Stanislaw R. Burzynski MD, PHD

About Stanislaw R. Burzynski MD, PHD

Dr. Burzynski, a nationally and internationally recognized physician/investigator, pioneered the use of biologically active peptides for the treatment of cancer. In 1967, at the age of 24, Dr. Burzynski graduated first in his class of 250 students from the Medical Academy in Lublin, Poland. It was at this time that he identified naturally occurring human peptides, which were deficient in cancer patients. He concluded that these peptides played a role in preventing the growth of cancer cells. In 1968, he earned a PhD degree and became one of the youngest physician/investigators in Poland to hold both a MD and PhD degree.

Between 1970 and 1977, he received funding from the National Cancer Institute (NCI) for his work as a Principal investigator and Assistant Professor at the Baylor College of Medicine in Houston, TX. During this time he authored/coauthored numerous publications, including those detailing his work on naturally occurring human peptides and their effect on cancer – some of which were co-authored by investigators associated with the M.D. Anderson Cancer Center or the Baylor College School of Medicine. In May 1977, Dr. Burzynski received a Certificate of Appreciation from the Baylor College of Medicine that acknowledged his contributions to the ‘Advancement of Medical Education, Research, and Health Care’.

In 1977 the Burzynski Clinic was established in Houston, TX. Since then, more than 10,000 patients have received treatment at the clinic, including more than 2,300 cancer patients who have been treated in FDA reviewed and Institutional Review Board (IRB) approved clinical trials program of Antineoplastons, investigational agents that derived from Dr. Burzynski’s early investigations of naturally occurring human peptides. Currently, new FDA-reviewed Phase II and III clinical studies utilizing Antineoplastons are awaiting funding approval prior to patient enrollment.

Dr. Burzynski has extensive experience treating cancer with combinations of targeted agents and immunotherapy, and the drug phenylbutyrate (PB), which targets multiple genetic abnormalities simultaneously.

Dr. Burzynski is the author/co-author of over 300 scientific publication/presentations. He has collaborated with investigators at the NCI, the Medical College of Georgia, the Imperial College of Science and Technology of London, the University of Kurume Medical School in Japan, and the University of Turin Medical School in Italy, among others. He is a member of several prestigious organizations, including the American Association of Cancer Research (AACR), the Society for Neuroscience, the Society for Neuro-oncology, the Royal Medical Association (U.K.), and the Academy of Medical Ethics. As of June 2015, he held 245 patents in 35 countries covering his scientific inventions.

 

CURRICULUM VITAE

Stanislaw R. Burzynski, M.D., Ph.D.

 

 

ACADEMIC TRAINING, CERTIFICATION AND LICENSURE   

Texas State Board of Medical Examiners

License to Practice Medicine, 1973

Baylor College of Medicine, Houston, Texas

ECFMG Certificate, 1971

Medical Academy, Lublin, Poland

M.D. with Distinction, 1967

Ph.D. (Biochemistry), 1968

 

POSITIONS HELD

Visiting Professor of Neuro-Oncology, Capital University in Beijing

Beijing, China, 2012 to present

Visiting Professor of Neuro-Oncology, Beijing Tiantan Hospital

Beijing, Tiantan, 2012 to present

Visiting Professor, Linyi People’s Hospital

Linyi City, China, 2012 to present

President, Burzynski Research Institute Inc.

Houston, TX, 1983 to present

Laboratory Director, Burzynski Clinic Laboratory

Houston, TX, 1979 to present

President, Burzynski Clinic

Houston, TX, 1977 to present

Assistant Professor, Baylor College of Medicine

Houston, Texas, 1972-1977

Research Associate, Baylor College of Medicine

Houston, Texas, 1970-1972

Intern and Resident, Medical Academy, Internship in the Departments of Surgery, Internal Medicine,

Pediatrics, Obstetrics and Gynecology, and Residency in the Department of Internal Medicine

Lublin, Poland, 1967-1970

Teaching Assistant, Medical Academy, Department of General Chemistry

Lublin, Poland, 1962-1967

Research Worker, Medical Academy, Department of General Chemistry

Lublin, Poland, 1961-1962

 

SCIENTIFIC AND PROFESSIONAL MEMBERSHIPS

American Academy of Anti-Aging Medicine

American Academy of Medical Ethics.

American Association for Advancement of Science

American Association for Cancer Research

American Association of Pharmaceutical Scientists

American Chemical Society

American Diabetes Association

American Medical Association

European Association for Neuro-Oncology

Harris County Medical Society

International Union of Pure and Applied Chemistry

New York Academy of Sciences

Parenteral Drug Association

Society for Neuro-Oncology

Society for Neuroscience

Texas Medical Association

The Royal Society of Medicine (U.K.)

The Society of Sigma Xi

World Medical Association

World Society of Anti-Aging Medicine

RESEARCH SUPPORT

National Cancer Institute Grantee, 1974-1977

Baylor College of Medicine Grantee, 1976

West Foundation Grantee, 1975

Medical Academy (Lublin, Poland) Grantee, 1962-1967

 

HONORS AND AWARDS

Lifetime Achievement Award from The Truth About Cancer, Nashville, TN, December 2015

Lifetime Achievement Award from the Academy of Comprehensive Integrative Medicine, Ft. Worth, TX, March, 2012

The Linus Pauling Award, October, 2008, ACAM

The Linus Pauling Award, February, 2008, Orthomolecular Health-Medicine

The Order of Merit of the President of Poland – Officer’s Cross, October, 2004

Decoration of Polish Medical Association, November, 2001

The Order of Saint Brigida – Grand Cross with Star, November, 2001

The Order of Saint Stanislas – Grand Cross with Star, November, 2000

The Order of Reconciliation – November, 2000

The Cross Virtus Nobilitat, June, 1999

The Wisdom Award of Honor, December, 1998

The Medal of the President of City of Lublin, Poland, December, 1998

The Order of Saint Stanislas- Commander’s Cross with Star, December, 1997

The Lady Liberty Award, July, 1997

The Gold Medal from the American Institute of Polish Culture for outstanding achievements in the field of medicine and discovery of anti-cancer drugs antineoplastons, Miami, FL, February, 1997

The Medal “Heart for Hearts” for saving human lives, Lublin, Poland, August, 1997

The Memorial Medal of Zamoyski’s Lyceum in appreciation of outstanding contribution to increase scientific ranking of the school, Lublin, Poland, November, 1997

The Heritage Award by Polish American Congress in recognition of extraordinary achievement in the research, treatment, and prevention of cancer, Chicago, IL, October, 1993.

Special Medal from the Polish government’s Institute for Drug Research and Control for achievement in the field of cancer research, Bialvstok, Poland, September, 1989

Honorable Membership in the Academia del Medeterraneo, Rome, Italy, 1984

Recipient of commendation for Dedicated Service and for Personal Contribution made in the

Advancement of Medical Education, Research and Health Care, Baylor College of Medicine, Houston, TX, April, 1977

Recipient of Medical Doctor Diploma with Distinction, Medical Academy, Lublin, Poland, 1967

Co-winner of the prize for best paper presented at the 7th Conference of Polish Medical Student Research

Societies, Poznan, Poland, 1966.

The Hereditary Title of Count

 

HONORABLE BIOGRAPHY

Biography published in Marquis, Who’s Who in the World, 8th  through 26th editions

Biography published in Marquis, Who’s Who in America, 51st through 65th editions

Biography published in Marquis, Who’s Who in Science and Engineering, 2nd through 6th editions

Biography published in Marquis, Who’s Who in Medicine and Healthcare, 1st through 6th editions

Biography published in Marquis, Who’s Who in Emerging Leaders in America, 1st edition

Biography published in Marquis, Who’s Who Frontiers of Science and Technology, 2nd edition

Biography published in American Men and Women of Science, 13th Edition, Jacques Catell Press

 

 

CHAIRMAN OF SCIENTIFIC SESSIONS AT INTERNATIONAL MEETINGS

Co-Chairman, BIT’s 8th Annual World Congress of NeuroTalk-2017, Barcelona, Spain, 2017

Dubai Congress on Anti-Aging & Aesthetic Medicine (DCAAAM), Dubai, UAE, 2008

1st Anti-Aging International Symposium and Exposition, Tokyo, Japan, 2006

International Conference in Integrative Medicine, Seattle, Washington, U.S.A, 1999

Comprehensive Cancer Care I Conference, Washington, D.C., U.S.A., 1998

18th International Congress of Chemotherapy, Stockholm, Sweden, 1993

17th International Congress of Chemotherapy, Berlin, Germany, 1991

9th International Symposium on Future Trends in Chemotherapy, Geneva, Switzerland, 1990

10th Congress of the Polish Pharmacological Society, Bialystok, Poland, 1989

8th International Symposium on Future Trends in Chemotherapy, Tirrenia, Italy, 1988

10th International Congress of Pharmacology, Sydney, Australia, 1987

 

INVITED LECTURES (given since 1988)

“Precision therapy of glioblastoma.” Keynote Speaker. Presented at BIT’s 8th Annual World Congress of NeuroTalk-2017, Barcelona, Spain, May 22-24, 2017.

“Cancer treatment in the Information Age. The cure is in sight.” Keynote Speaker. Presented at the Truth About Cancer: A Global Quest, Nashville, TN, October 14, 2016.

“Personalized targeted cancer therapy revolution.”  Keynote Speaker.  Presented at the 8th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies Expo, and the 2nd Annual Asia-Pacific Anti-Aging Medicine Summit, Beijing, China, October 25, 2013.

“Clinical trials with Antineoplastons. Long-term survival and quality of life.”  Keynote Speaker.  Presented at the 8th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies Expo, and the 2nd Annual Asia-Pacific Anti-Aging Medicine Summit, Beijing, China, October 26, 2013.

“Antineoplastons, chemistry, mechanism of action, design, and criticism of clinical trials.”  Keynote Speaker.  Presented at the Integrative Cancer Therapy – Module VI, San Diego, CA, June 6, 2013.

“Prospective clinical trials with antineoplastons for inoperable brain tumors in children.”  Keynote Speaker.  Presented at the Integrative Cancer Therapy – Module VI, San Diego, CA, June 6, 2013.

“Phase 2 prospective clinical trials for inoperable brain tumors in adults.”  Keynote Speaker.  Presented at the Integrative Cancer Therapy – Module VI, San Diego, CA, June 6, 2013.

“Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Studies in children.”  Keynote Speaker.  Presented at the Philippine Society of Pediatric Oncology 2012 Annual Convention in Ilo ilo, Philippines, October 27, 2012.

“Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Update.”  Presented at the Makati Medical Center in Manila, Philippines, October 25, 2012.

“Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Studies in children.”  Keynote Speaker.  Presented at St. Lukes Medical Center in Manila, Philippines, October 24, 2012.

“Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Studies in adults.”  Keynote Speaker.  Presented at St. Lukes Medical Center in Manila, Philippines, October 24, 2012.

“Phase II clinical trials of Antineoplastons in pediatric brain tumors and adult brain tumors.”  Keynote Speaker. Presented at the “2012 Shanghai World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies Expo (A4MC-2012),” at the Shanghai World Expo Exhibition & Convention Center in Shanghai, China, October 18, 2012.

“The future is full of hope: Cancer treatment based on genomic testing.”  Keynote Speaker. Presented at the “Hope for the Hopeless Conference,” at the American Airlines Training & Conference Center in Ft. Worth, TX, March 9, 2012.

“Molecular Profiling in Oncology Practice: The Results of Treatment in a Group of 1,633 Patients.”  Presented at “BIT’s 4th Annual World Cancer Congress – 2011,” Dalian, China, May 24, 2011.

“Epigenomic Approach to Cancer Treatment.”  Keynote Speaker. Presented at the “45th Annual Meeting of the American Academy of Environmental Medicine,” San Diego, CA, October 21, 2010.

“Genomic and Epigenomic Principles of Cancer Treatment.”  Keynote Speaker. Presented at the “10th Scientific Meeting of the Japanese Society of Anti-Aging Medicine,” Kyoto, Japan, June 12, 2010.

“Genomic and Epigenomic Principles of Cancer Treatment.”  Presented for 50 doctors at Keiko University, Tokyo, Japan, June 9, 2010.

“Genomic and Epigenomic Principles of Cancer Treatment.”  Presented for 10-20 doctors at Tokai University, Tokyo, Japan, June 8, 2010.

“Antineoplastons.”  Presented for Antineoplastons Study Group of Japan, Tokyo, Japan, May 13, 2009.

“Mechanisms of Anti-Tumor Activity in Synthetic Antineoplastons.”  Presented for Antineoplastons Study Group of Japan, Tokyo, Japan, May 13, 2009.

“Practical Application of Gene Silencing Theory of Aging.  Life Extension in Animals and Human Clinical Trials.”  Presented at the “Dubai Congress on Anti-Aging & Aesthetic Medicine (DCAAAM),” Dubai, UAE, 2008

“Antineoplastons and Targeted Gene Therapy.”  Presented at the “ACAM Las Vegas,” Las Vegas, Nevada, October 15-19, 2008

“Genome, Epigenome and Aging.”  Presented at the “First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies,” Estoril, Portugal, May 29-31, 2008

“Personalized Cancer Treatment in Genomics Era.”  Presented at the “First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies,” Estoril, Portugal, May 29-31, 2008

“Anti-Aging Peptides – A New Frontier in Healing.”  Presented at the “2008 Orthomolecular Health-Medicine conference,” San Francisco, CA, February 2008.

“Antineoplaston Peptides in Treating Cancer.”  Presented at the “2008 Orthomolecular Health-Medicine conference,” San Francisco, CA, February 2008.

“Personalized Cancer Treatment.” Presented at the “2007 Total Health and Recovery Expo” in The Woodlands, Texas, October 20, 2007

“Cancer Treatment in Genomics Era.” Hosted by the Lions Health First Foundation, at the Hilton in Las Vegas, Nevada, September 15, 2007

“The Genetic Solution for Anti-Aging.”  Presented at the “Healthy Directions Conference,” hosted by Dr. Julian Whitaker at the Marriott Westchase in Houston, Texas, January 6, 2007

“The Genetic Solution for Anti-Aging.” Presented at 11th Cruising for Health and Wealth, January 2006

“New Cancer Treatments and Anti-Aging Regimens.”  Presented at the “Polish Club of Leisure World,” in Laguna Woods, California, March 13, 2005

“Mechanizmy I profilaktyka genetycznego starzenia (Mechanisms and Prevention of Genetic Aging).”  Presented at the “Ogolnoeuropejska Konferencja Naukowo-Szkoleniowa Polskiego Towarzystwa Neurologicznego,” in Lublin, Poland, September (wrzesień) 22-25, 2004

“Regulation of Gene Expression in Cancer and Aging.”  Presented at “Innovations in      Complementary/Integrative Healthcare,” in Phoenix, Arizona, September 5-7, 2003

“Treatment of Cancer with Antineoplastons: Effect on Genes and Protein Metabolism.”
Presented at the “12th Annual Scientific Symposium,” in Orlando, Florida, August 27-31, 2003

“Gene Silencing in Cancer and Aging”. Presented at Graduation Ceremony: Ultrasound Diagnostic

School, November 15, 2002

“Antineoplaston Treatment of Cancer – Results of American and Japanese Clinical Trials.”  Presented at

ABEIM – A Cancer Symposium, Fort Worth, Texas, 2002

“Antineoplaston Cancer Treatment – Theory and Results”; “Cancer and Aging – The Connection”;

“Controlling the Key Aging Process of Methylation and Acetylation with the New Category of Anti-Aging Compounds and Antineoplastons.”  Presented at the 6th International Symposium on Anti-Aging Medicine, Costa Rica, Los Suenos, August 23-24, 2002

“Treatment and Prevention of Cancer with Antineoplastons,” Presented in Santiago, Chile, July 3, 2002

“Antineoplastons –Theory and Treatment,” Presented at Seminar for Physicians: Sanoviv, Baja

California, June 13, 2002

“Treatment of Brain Tumors with Antineoplastons A10 and AS2-1.” Presented at Hyman-Newman

Institute for Neurology and Neurosurgery, Beth Israel Hospital, New York, August 22, 2001

“Treatment of Brain Tumors with Antineoplastons A10 and AS2-1”, Presented at Therapeutic Good

Administration (TGA) of Australia, Canberra, Australia, July 17, 2001

“Antineoplastons.” Presented at Polish Medical Association, Warsaw, Poland, November 22, 2000.

“Treatment of Cancer with Antineoplastons.” Presented at Symposium organized by People Against Cancer in Stuttgart and Munich, Germany, for General Audience, November, 1999

“Antineoplastons:  A Breakthrough in Cancer Therapy.”  Presented at Manila Doctors Hospital, Manila,   The Philippines, November 9, 1998

“The New Breakthrough in Cancer.”  Presented at Marian Cancer Foundation, Manila, The Philippines,    November 6, 1998

“Antineoplastons.” Presented at “Surviving Cancer.” Westminster Central Hall, London, U.K.,

November 15, 1997

“Antineoplastons:  Theory and Clinical Trials.” Presented at Medical Academy, Lublin, Poland,

November 7, 1997

“Biochemical Defense System.”  Presented at Medical Academy, Lodz, Poland, July 24, 1992

“Treatment of AIDS and HIV Infection with Antineoplastons AS2-1”. Presented at Search Alliance, Los

Angeles, California, November 20, 1991

“Cancer, AIDS and the other Immune System”. Presented at Foundation for the Advancement of Innovative Medicine, New York, NY, October 26, 1991

“Antineoplastons.” Presented at World Research Foundation Congress, Los Angeles, California,

October 7, 1990

“Antineoplastons—New Methods of Cancer Treatment.” Presented at Polish Pharmacological Society,

Lublin, Poland, August 29, 1989

“Clinical Results of Antineoplaston Therapy.” Presented at Kurume University School of Medicine,

Kurume, Japan, April 9, 1988

“Mechanism of Action of Antineoplaston A10 and Experimental Data.” Presented at Kurume University

School of Medicine, Kurume, Japan, April 8, 1988

“Isolation, Purification and Synthesis of Antineoplastons.” Presented at Kurume University School of

Medicine, Kurume, Japan, April 8, 1988

 

EDITORIAL POSITIONS

Reviews on recent clinical trials, Bentham Science Publishers, Editor-In-Chief.

 

BOOK CHAPTERS, MONOGRAPHS AND ARTICLES

BY S.R. BURZYNSKI AND ASSOCIATES

 

  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of Antineoplastons A10 and AS2-1 in children with brain tumors. Final report (Protocol BT-10). J Cancer Ther 2017; 8:173-187.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. Antineoplastons A10 and AS2-1 in the treatment of children with optic pathway glioma: Final report for Protocol BT-23. Cancer Clin Oncol 2017; 6(1):25-35.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. Primary CNS tumors and leptomeningeal, disseminated and/or multicentric disease in children treated in phase II studies with antineoplastons A10 and AS2-1. Cancer Clin Oncol 2016; 5(2):38-48.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in children with low-grade astrocytomas–Final report (Protocol BT-13). J Cancer Ther 2016; 7(12):837-850.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. Comprehensive genomic profiling of recurrent classic glioblastoma in a patient surviving eleven years following antineoplaston therapy. Cancer Clin Oncol 2015; 4(2):41-52.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in adult patients with primary brain tumors – Final report (Protocol BT-09). J Cancer Ther 2015; 6(12):1063-1074.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent anaplastic astrocytoma. Final report (Protocol BT-15). Cancer Clin Oncol 2015;4(2):13-23.
  • Burzynski, S.R., Burzynski, G.S., Marszalek, A., Janicki, T.J., Martinez-Canca, J.F. Long-term survival over 21 years and pathologically confirmed complete response in pediatric anaplastic astrocytoma: A case report. J Neurol Stroke 2015;2(6):00072.
  • Burzynski, S.R., Burzynski, G.S., Marszalek, A., Janicki, T.J., Martinez-Canca, J.F. Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma treated with antineoplastons A10 and AS2-1. J Neurol Stroke 2015;2(3):00054.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in patients with brainstem gliomas.  The report on non-diffuse intrinsic pontine glioma (Protocol BT-11). J Cancer Ther 2015;6:334-344.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in adult patients with newly-diagnosed anaplastic astrocytoma. Final report (Protocol BT-08). Cancer Clin Oncol 2015;4(1):28-38.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. Complete response and long-term survival (>20 years) of a child with tectal glioma: A case report. Pediatr Neurosurg 2015;50(2):99-103.
  • Burzynski, S.R., Burzynski, G.S., Brookman, S. A case of sustained objective response of recurrent/progressive diffuse intrinsic pontine glioma with phenylbutyrate and targeted agents. J Cancer Ther 2015;6:40-44.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy with pazopanib and other agents in combination with sodium phenylbutyrate in the treatment of glioblastoma multiforme. J Cancer Ther 2014;5:1423-1437.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in colorectal cancer after failure of second-line therapy – A potential strategy for improved survival. J Cancer Ther 2014;5:1270-1288.
  • Burzynski, S.R., Burzynski, G.S. Long-term progression-free survival of recurrent glioblastoma multiforme treated with a combination of targeted agents: A case report. AT-14. Neuro Oncol 2014;16(Suppl. 5):v11.
  • Burzynski, S.R., Janicki, T.J., Marszalek, A., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in patients with brainstem gliomas final report (Protocol BT-11). AT-15. Neuro Oncol 2014;16(Suppl. 5):v11.
  • Janicki, T.J., Burzynski, G.S., Burzynski, S.R. Long-term survival (over 15 years) of pathologically confirmed recurrent glioblastoma multiforme: A case report. AT-28. Neuro Oncol 2014;16(Suppl. 5):v14-15.
  • Burzynski, G.S., Janicki, T.J., Marszalek, A., Burzynski, S.R. Long-term survival (>20 years) of a child with brainstem glioma treated with antineoplastons A10 and AS2-1: A case report. PT-02. Neuro Oncol 2014;16(Suppl. 5):v175.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in recurrent advanced pancreatic cancer – A potential strategy for improved survival. J Cancer Ther 2014;5:1072-1091.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in advanced malignant mesothelioma: A strategy for improved survival. J Cancer Ther 2014;5:1127-1144.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme. Final report (Protocol BT-21). J Cancer Ther 2014;5:946-956.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A., Brookman, S. A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors. Final report (Protocol BT-22). J Cancer Ther 2014;5:977-988.
  • Burzynski, S.R., Burzynski, G.S., Janicki, T.J. Recurrent glioblastoma multiforme, a strategy for long-term survival. J Cancer Ther 2014;5:957-976.
  • Burzynski, S.R., Patil, S.S. The effect of antineoplastons A10 and AS2-1 and metabolites of sodium phenylbutyrate on gene expression in glioblastoma multiforme. J Cancer Ther 2014;5:929-945.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in children with high-grade glioma. Final report (Protocol BT-06), and review of recent trials. J Cancer Ther 2014;5:565-577.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Child’s Nervous System 2014;30(12):2051-2061.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. Long-term survival (> 13 years) in a child with recurrent diffuse pontine gliosarcoma: the case report.  Journal of Pediatric Hematology/Oncology 2014;36(7):e433-e439. doi: 10.1097/MPH.0000000000000020.
  • Aliev, G., Burzynski, G., Ashraf, G.M., Jabir, N.R., Cacabelos, R., Benberin, V.V., Burzynski, S.R. Implication of oxidative stress-induced oncogenic signaling pathways as a treatment strategy for neurodegeneration and cancer.  Syst Biol Free Rad Antioxid 2014; 2325-2347; DOI: 10.1007/978-3-642-30018-9.
  • Burzynski, S.R., Janicki, T., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors based on protocol BT-22. CT-004.  Neuro-Oncology 2014;16(Suppl. 1):i10.
  • Burzynski, G., Janicki, T., Burzynski, S.R., Marszalek, A. Long-term survival (over 20 years) and pathologically confirmed complete response in pediatric anaplastic astrocytoma: a case report. HG-017.  Neuro-Oncology 2014;16(Suppl. 1):i44.
  • Janicki, T., Burzynski, S.R., Burzynski, G., Marszalek, A. Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma (PNET) without recurrence: a case report. MB-039-020.  Neuro-Oncology 2014;16(Suppl. 1):i80.
  • Burzynski, G., Burzynski, S.R., Janicki, T., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme based on protocol BT-21. NO-020.  Neuro-Oncology 2013;15(Suppl. 3):iii103.
  • Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in pediatric recurrent diffuse intrinsic pontine glioma. NO-021.  Neuro-Oncology 2013;15(Suppl. 3):iii103.
  • Janicki, T., Burzynski, S., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 (ANP) in children with high-grade glioma (Protocol BT-06). NO-058.  Neuro-Oncology 2013;15(Suppl. 3):iii112.
  • Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. Long-term survival (over 13 years) in a child with recurrent diffuse pontine gliosarcoma: A case report. NO-089.  Neuro-Oncology 2013;15(Suppl. 3):iii120.
  • Aliev, G., Palacios, H.H., Cacabelos, P., Cacabelos, R., Burzynski, G., Burzynski, S.R. Mitochondria specific antioxidants and their derivatives in the context of the drug development for neurodegeneration and cancer.   Drug Designing 2013;2(1):103.
  • Patil, S.S., Mrowczynski, E., Grela, K., Burzynski, S.R. Phenylacetylglutaminate in combination with phenylbutyrate effectively inhibits growth of brain tumor cells in vitro.  Neuro-Oncology 2012;14(Suppl. 3):iii16.
  • Patil, S.S., Burzynski, S.R., Mrowczynski, E., Grela, K., Chittur, S.V. Phenylacetylglutaminate and phenylacetate in combination upregulate VDUP1, cause cell cycle blockade and apoptosis in U87 glioblastoma cells.  Journal of Cancer Therapy 2012;3:192-200.
  • Paleolog, J., Strachecka, A., Burzynski, S.R., Olszewski, K., Borsuk, G. The larval diet supplemented with sodium phenylacetylglutaminate influences the worker cuticle proteolytic system in honeybees (Apis mellifera).  Journal of Apicultural Science 2011;55(2):73-83.
  • Burzynski, S.R, Nagy-Kubove, E. Treatment of esthesioneuroblastoma and non-small cell lung cancer with phenylbutyrate.  Journal of Cancer Therapy 2011;2:518-522.
  • Burzynski, S.R, Marquis, A., Nagy-Kubove, E., Janicki, T.J. Successful treatment of recurrent triple-negative breast cancer with combination of targeted therapies.  Journal of Cancer Therapy 2011;2:372-376.
  • Burzynski, S.R, Weaver, R.A., Janicki, T.J., Burzynski, G.S., Szymkowski, B., Acelar, S.S. OT-15. Preliminary results of a phase II study of antineoplastons A10 and AS2-1 (ANP) in adult patients with recurrent mixed gliomas.  Neuro-Oncology 2010;12(Suppl. 4):iv72.
  • Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K. CB-15. Targeting microRNAs in glioma cells with antineoplastons.  Neuro-Oncology 2010;12(Suppl. 4):iv10.
  • Burzynski, S.R, Weaver, R.A., Janicki, T., E, Szymkowski, B., Acelar, S.S., Burzynski, G.S. A phase II study of antineoplaston A10 and AS2-1 injections in children with low-grade astrocytomas.  Neuro-Oncology 2010;12(6):ii95.
  • Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K. Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells.  Neuro-Oncology 2010;12(6):ii87.
  • Weaver, R.A., Szymkowski, B., Burzynski, S.R. Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP).  Neuro-Oncology 2009;11:923.
  • Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B., Burzynski, G.S. Phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma: Protocol BC-BT-11.  Neuro-Oncology 2009;11:951.
  • Burzynski, S.R. The coming pandemic of liver cancer: In search of genomic solutions.  In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume XI;2009.
  • Burzynski, S.R. Practical application of gene silencing theory of aging. Life extension in animal testing and human clinical trials.  In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume XI;2009.
  • Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K. The ingredients of antineoplaston AS2-1 down-regulate glycolysis pathways in glioblastoma cells.  Neuro-Oncology 2008;10:1148.
  • Burzynski, S., Weaver, R., Janicki, T., Szymkowski, B., Burzynski, G. Phase II study of antineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma.  Neuro-Oncology 2008;10:1067.
  • Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K. Antineoplaston AS2-1 affects cell cycle checkpoints, leading to apoptosis in human glioblastoma cells.  Neuro-Oncology 2008;10:786.
  • Burzynski, S., Weaver, R., Janicki, T., Burzynski, G., Samuel, S., Szymkowski, B. Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma: A preliminary report.  Neuro-Oncology 2008; 10:821.
  • Burzynski, S.R., Weaver, R., Janicki, T., Walczak, M., Szymkowski, B., Samuel, S. Phase II study of antineoplastons A10 and AS2-1 (ANP) in children with optic pathway glioma: A preliminary report.  Neuro-Oncology 2008;10:450.
  • Burzynski, S.R. The genes of life.  Farmapress Publishers, 2008.
  • Burzynski, S.R. Genomic approach to cancer treatment.  In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume X; 2008;37-44.
  • Burzynski, S.R. Recent clinical trials in diffuse intrinsic brainstem glioma.  Cancer Therapy 2007;5, 379-390.
  • Burzynski, S.R., Weaver, R., Szymkowski, B. A case report of a complete response and 20-year survival of a patient with a recurrent diffuse intrinsic brainstem anaplastic astrocytoma.  Neuro-Oncology 2007;9:536.
  • Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. Phenylacetylglutamine (PG) and phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells.  Neuro-Oncology 2007;9:482.
  • Burzynski, S.R. The Genetic Solution for Anti-Aging.  In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007;63-70.
  • Burzynski, S.R. Genetics of Brain Aging (I). Gene Silencing in Neurons.  In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007;71-78.
  • Burzynski, S.R. Genetics of Brain Aging (II).  Genetic Mechanisms in Encoding and Consolidation of Memory.  In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007;79-88.
  • Burzynski, S.R., Weaver, R.A., Janicki, T.J., Jurida, G.F., Szymkowski, B.G., Kubove, E. Phase II studies of Antineoplastons A10 and AS 2-1 (ANP) in children with newly diagnosed diffuse, intrinsic brainstem gliomas.  Neuro-Oncology 2007;9:206.
  • Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (5).  Genes and aging of the neurons.  Geny a starzenie neuronow.  Czasopismo Aptekarskie 2007; Nr 3 (159) 27-38.
  • Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (4).  Time factor in biology and medicine.  Czynnik czasu w biologii i medycynie.  Czasopismo Aptekarskie 2007; Nr 2 (158) 27-36.
  • Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (3). The medicine of aging population. Medycyna starzejacego sie spoleczenstwa.  Czasopismo Aptekarskie 2007; Nr 1 (157) 39-48.
  • Burzynski, S.R. Targeted Therapy for Brain Tumors.  Columbus F, ed. Brain Cancer Therapy and Surgical Interventions. New York (NY); Nova Science Publishers, Inc. 2006;77-111.
  • Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (2).  Epigenome and gene silencing.  Epigenom i wyciszanie genow.  Czasopismo Aptekarskie 2006;Nr 12 (156) 29-36.
  • Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (1). The medicine of genome an epigenome. Medycyna genomu i epigenomu.  Czasopismo Aptekarskie 2006;Nr 11 (155) 45-52.
  • Burzynski, S.R. Age Management Treatments Which Target Silenced Genes.  Redberry GW, ed.  Gene Silencing: New Research.  Nova Science Publishers, Inc. 2006.
  • Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.G., Khan, M.I., Dolgopolov, V. Treatment of multicentric brainstem gliomas with antineoplastons (ANP) A10 and AS2-1.  Neuro-Oncology. 2006;10:466.
  • Burzynski, S.R., Weaver, R.A., Szymkowski, B., Janicki, T.J., Khan, M.I., Dolgopolov, V. Complete response of a diffuse intrinsic brainstem tumor and von Hippel Lindau (VHL) disease to antineoplastons A10 and AS2-1 (ANP): a case report.  Neuro-Oncology. 2006;10:439.
  • Burzynski, S.R. Treatments for Astrocytic Tumors in Children: Current and Emerging Strategies.  Pediatric Drugs 2006;8:167-178.
  • Burzynski, S.R., Janicki, T.J., Weaver, R.A., Burzynski, B. Targeted therapy with Antineoplastons A10 and AS2-1 of high grade, recurrent, and progressive brainstem glioma.  Integrative Cancer Therapies 2006; 5(1):40-47.
  • Burzynski, S.R., Weaver, R.A., Janicki, T.J., Szymkowski, B.G., Jurida, G.F., Burzynski, B. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in patients with recurrent, diffuse intrinsic brain stem gliomas.  Neuro-Oncology 2006;10:346.
  • Burzynski, S.R. Master Clock of Life (II). How to Turn the Clock Back. In: American Academy of Anti-Aging Medicine.  American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics;Volume VIII 2006.
  • Burzynski, S.R. Master Clock of Life (I). “Junk DNA.” and Promoters Regions as Major Components of the Clock.  American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics;Volume VIII 2006.
  • Burzynski, S. R. Gene silencing theory of aging: the clinical trial supporting the theory.  Anti-Aging Therapeutics 2005;Vol VII:39-46.
  • Burzynski, S.R., Weaver, R.A., Janicki, T.J., Burzynski, B., Jurida, G. Targeted therapy with ANP in children less than 4 years old with inoperable brain stem gliomas.  Neuro-Oncology 2005;7:300.
  • Weaver, R.A., Burzynski, S.R., Janicki, T.J., Burzynski, B., Jurida, G., Szymkowski, B. Long-term survival in patients with glioblastoma multiforme treated in phase II studies with ANP.  Neuro-Oncology 2005;7:299.
  • Burzynski, S.R., Weaver, R.A., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with Antineoplastons A10 AS2-1.  Integrative Cancer Therapies 2005;4(2):168-177.
  • Burzynski, S.R. Aging: Gene silencing or gene activation?  Med Hypoth 2005; 64, 201-208.
  • Burzynski, S.R. Mechanizmy i profilaktyka genetycznego starzenia.  Mechanisms and prevention of genetic aging.  Neurologia I Psychiatria 2004;4:1-8.
  • Burzynski, S.R., Ilkowska-Musial, E., Klimczak M.W., Musial, L.  Antineoplastons In Dairy Products.  Journal of Applied Nutrition 2004;54;1-8.
  • Burzynski, S.R., Weaver, R. Bestak. , Lewy, R.I., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.  Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma.  Neuro-Oncology 2004;6:386.
  • Weaver, R.A., Burzynski, S.R., Bestak, M., Lewy, R.I., Janicki, T.J., Szymkowski, B., Jurida, G., Khan, M.I., Dolgopolov, V. Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme.  Neuro-Oncology 2004;6:384.
  • Burzynski, S.R., Weaver, R. Bestak. , Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V. Treatment of primitive neuroectodermal tumors (PNET) with antineoplastons A10 and AS2-1 (ANP). Preliminary results of phase II studies.   Neuro-Oncology 2004;6:428.
  • Burzynski, S.R., Weaver, R. Bestak. , Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in children with atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system.  A preliminary report.  Neuro-Oncology 2004;6:427.
  • Burzynski, S.R., Lewy, R.I., Weaver, R., Janicki, T., Jurida, G., Khan, M., Larisma, C.B., Paszkowiak, J., Szymkowski, B. Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme.   Integrative Cancer Therapies 2004;3:257-261.
  • Burzynski, S.R., Weaver, R., Lewy, R., Janicki, T. Jurida, G., Szymkowski, B., Khan, M., Bestak, M.  Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma. A Preliminary Report.  Drugs R&D 2004;5(6):315-326.
  • Burzynski, S.R. The Present State of Antineoplaston Research.  Integrative Cancer Therapies 2004;3:47-58.
  • Burzynski, S.R., Lewy, R.I., Weaver, R.A., Axler, M.L., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I., Bestak, M. Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Recurrent Diffuse Intrinsic Brain Stem Glioma (Preliminary Report).  Drugs in R&D 2003;4:91-101.
  • Waldbillig R, Burzynski SR. Mechanism of action, uptake, and gene array studies on the antineoplastic agent phenylacetylglutamine (PG) in human glioma cells U-87.  Neuro-Oncology 2003;10:309.
  • Burzynski, S.R., Weaver, R.A., Bestak, M., Lewy, R.I., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I. Phase II study of Antineoplastons A10 and AS2-1 (ANP) in children with recurrent and progressive multicentric glioma. A preliminary report.  Neuro-Oncology 2003;10:358.
  • Burzynski, S.R. The Methylation Control of Gene Activation and Silencing Theory.  The Basic Principles and Practice of Anti-Aging Medicine & Age Management for the Aesthetic Surgeon and Physician. Vincent C. Giampapa (Ed.) 2003;33-4.
  • Burzynski, S.R., Axler, M.L., Lewy, R.I., Janicki, Tomasz, Ilkowska-Musial, Elwira, Baranowska, Anna. Amino Acid Supplementation in Treatment of Cancer-Related Symptoms.  Journal of Applied Nutrition 2003; 53:52-60.
  • Burzynski, S. R. Gene Silencing – A New Theory of Aging.  Med Hypoth 2003; 60:578-583.
  • Burzynski, S.R.   In: Clinician’s Complete Reference To Complementary/Alternative Medicine, Novey, D. W. (Ed.).  Mosby 2000;496-507, St.Louis, USA.
  • Burzynski, S.R. The Best of Alternative Medicine.  Townsend Letter for Doctors 2000;200:32.
  • Burzynski, S.R., Conde, A.B., Peters, A., Saling B., Ellithorpe, R., Daugherty, J.P., and Nacht, C.H. A Retrospective Study of Antineoplastons A10 and AS2-1 in Primary Brain Tumors.  Drug Invest 1999;18:1-10.
  • Burzynski, S.R. Efficacy of Antineoplastons A10 and AS2-1.  Mayo Clin. Proc 1999;74:641-643.
  • Burzynski, S.R. Antineoplastons in the treatment of malignant brain tumors.  Anti-Aging Medical Terapeutics, vol. 2. Klatz RM., Goldman R. (Ed), Health Quest Publications 1998;28-34, Marina del Rey, Ca, USA.
  • Burzynski, S.R. Antineoplastons, oncogenes and cancer.  Anti-Aging Medical Therapeutics, Vol.1. Klatz RM, Goldman R. (Ed), Health Quest Publication 1997; Marina del Rey, CA, USA.
  • Burzynski, S.R. Potential of antineoplastons in diseases of old age.  Drugs & Aging 1995;7:157-167.
  • Soltysiak-Pawluczuk, D., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z. Cellular accumulation of antineoplaston AS2-1 in human hepatoma cells.  Cancer Letters 88 (1995);88:107-112.
  • Juszkiewicz, M., Chodkowska, A., Burzynski, S.R., Mlynarczyk, M., Kleinrok, Z. The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors.  Drugs Exptl Clin Res 1995;21:153-156.
  • Juszkiewicz, M., Chodkowska, A., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z. The influence of antineoplaston A5 on the central dopaminergic structures.  Drugs Exptl Clin Res 1994;20:161-167.
  • Burzynski, S.R. Immunosurveillance versus chemosurveillance.  Post Nauk Med 1993;6:260-262.
  • Burzynski, S.R. Antineoplastons, An Investigational Cancer Therapy.  Townsend Letter for Doctors 1993;3,150-153.
  • Burzynski, S.R. Novel differentiation inducers.  Recent Advances in Chemotherapy.  Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany.
  • Liau, M.C., Liau, C.P., Burzynski, S.R. Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals.  Internat J Exptl Clin Chemother 1992;5:9-17.
  • Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R. Prevention of drug induced DNA hypermethylation by antineoplaston components.  Internat J Exptl Clin Chemother 1992;5:19-27.
  • Lee, S.S., Burzynski, S.R. Synergistic Effect of Antineoplaston A5 and Retinoic Acid on the Induction of Human Promyelocytic Leukemia line HL-60.  Recent Advances in Chemotherapy.  Adam D. (Ed), Futuramed Publishers. 1992:  Munich, Germany.
  • Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R. Prevention of drug-induced DNA hypermethylation by antineoplastons.  Recent Advances in Chemotherapy.  Adam D.  (Ed), Futuramed Publishers. 1992; Munich, Germany.
  • Burzynski, S.R, Kubove, E., Burzynski, B. Phase II clinical trials of antineoplastons A10 and AS2-1 infusions in astrocytoma.  Recent Advances in Chemotherapy.  Adam D.  (Ed), Futuramed Publishers. 1992; Munich, Germany.
  • Lee, S.S., Burzynski, S.R. Antineoplaston A5:  A growth inhibitor for cancerous cells and growth stimulator for normal cells.  Internat J Exptl Clin Chemother 1991;4:63-65.
  • Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Protective effect of antineoplaston A10 in hepatocarcinogenesis induced by aflatoxin B1.  Internat J Tissue Reactions 1990;12 (suppl):43-50.
  • Liau, M.C., Lee, S.S., Burzynski, S.R. Modulation of cancer methylation complex isoenzymes as a decisive factor in the induction of terminal differentiation mediated by antineoplaston A5.  Internat J Tissue Reactions 1990; 12 (suppl): 27-36.
  • Lee, S.S., Burzynski, S.R. Inducibility of HL-60 leukemic cells to undergo terminal differentiation after repeated treatment with antineoplaston A5.  Internat J Exptl Clin Chemother 1990;3:125-128.
  • Lee, S.S., Burzynski, S.R. Induction of differentiation of HL-60 human promyelocytic leukemic cell by antineoplaston A5.  Internat J Tissue Reactions 1990;12(suppl):37-42.
  • Liau, M.C., Ashraf, A.Q., Lee, S.S., Hendry, L.B., Burzynski, S.R. Riboflavin as a minor active   anticancer component of antineoplaston A2 and A5.  Internat J Tissue Reactions 1990;12:19-26.
  • Liau, M.C., Lee, S.S., Burzynski, S.R. Separation of active anticancer components of antineoplaston A2, A3, and A5.  Internat J Tissue Reactions 1990; 12 (suppl): 1-17.
  • Burzynski, S.R., Kubove, E., Burzynski, B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1.  Drugs Exptl Clin Res 1990;16: 361-369.
  • Burzynski, S.R. Isolation, purification and synthesis of antineoplastons.  Internat J Exptl Clin Chemother 1989;2:63-69.
  • Liau, M.C., Lee, S.S., Burzynski, S.R. Hypomethylation of nucleic acids:  A key to the induction of terminal differentiation.  Internat J Exptl Clin Chemother 1989;2:187-199.
  • Hendry, L.B., Muldoon, T.G., Burzynski, S.R. Modeling studies suggest the modified dipeptide analog phenylacetylamino-2, 6-piperidinedione may interact with DNA.  Adv Exptl Clin Chemother. 1988; 2: 11-13.
  • Burzynski, S.R. Antineoplastons: Basic research and clinical applications.  Adv Exptl Clin Chemother. 1988; 2: 1-9.
  • Burzynski, S.R. Isolation, purification and synthesis of antineoplastons.  Adv Exptl Clin Chemother. 1988; 6: 1-7.
  • Liau, M.C., Lee, S.S, Burzynski, S.R. Differentiation inducing components of antineoplaston A5.  Adv Exptl Clin Chemother. 1988; 6: 9-25.
  • Lee, S.S., Burzynski, S.R. Terminal differentiation of HL-60 human promyelocytic leukemia cells induced by antineoplaston A2.  Adv Exptl  Clin Chemother 1988;6:27-31.
  • Burzynski, S.R. Treatment of bladder cancer with antineoplaston formulations.  Adv Exptl Clin Chemother. 1988. 2: 37-46.
  • Burzynski, S.R., Kubove, E., Burzynski, B. Phase I clinical studies of oral formulation of antineoplaston AS2-1.  Adv Exptl Clin Chemother 1988;2:29-36.
  • Burzynski, S.R. Treatment of malignant brain tumors with antineoplastons.  Adv Exptl Clin Chemother 1988;6:45-56.
  • Ashraf, A.Q., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic analysis of antineoplaston A10 injections following intravenous administration in rats.  Adv Exptl Clin Chemother 1988;6:33-39.
  • Ashraf, A.Q., Burzynski, S.R. Comparative study of antineoplaston A10 levels in plasma of healthy people and cancer patients.  Adv Exptl Clin Chemother 1988;2: 19-28.
  • Lee, S.S., Burzynski, S.R. Tissue culture and animal toxicity studies of antineoplaston A5.  Drugs Exptl Clin Res 1987;13 (suppl 1):31-35.
  • Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Chemoprevention by antineoplaston A10 of benzo (a) pyrene-induced pulmonary neoplasia.  Drugs Exptl Clin Res 1987;13 (suppl 1):51-55.
  • Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R. Chemosurveillance: A novel concept of the natural defense mechanism against cancer.  Drugs Exptl Clin Res 1987;13 (suppl 1):71-76.
  • Lee, S.S., Mohabbat, M.O., Burzynski, S.R. In vitro cancer growth inhibition and animal toxicity studies of antineoplaston A3.  Drugs Exptl Clin Res 1987;13 (suppl 1):13-16.
  • Khalid, M., Burzynski, S.R. N,N’-disubstituted L-isoglutamines as novel cancer  chemotherapeutic agents.  Drugs Exptl Clin Res 1987;13 (suppl 1):57-60.
  • Hendry, L.B., Muldoon, T.G., Burzynski, S.R., Copland, J.A., Lehner, A.F. Stereochemical modeling studies of the interaction of antineoplaston A10 with DNA.  Drugs Exptl Clin Res 1987;13 (suppl 1):77-81.
  • Burzynski, S.R., Kubove, E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years follow-up.  Drugs Exptl Clin Res 1987;13 (suppl 1):1-12.
  • Burzynski, S.R., Kubove, E. Phase I clinical studies of antineoplaston A3 injections.  Drugs Exptl Clin Res 1987;13 (suppl 1):17-29.
  • Burzynski, S.R., Kubove, E., Burzynski, B. Phase I clinical studies of antineoplaston A5 injections.  Drugs Exptl. Clin Res 1987;13 (suppl 1):37-43.
  • Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R. Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy.  Drugs Exptl Clin Res 1987;13 (suppl 1):61-70.
  • Ashraf, A.Q., Liau, M.C., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic study of radioactive antineoplaston A10 following oral administration in rats.  Drugs Exptl Clin Res 1987;13 (suppl 1):45-50.
  • Burzynski, S.R., M.O.  Chronic animal toxicity studies of antineoplaston A2.  Drugs Exptl Clin Res 1986;12 (suppl 1):73-75.
  • Ashraf, A.Q., Liau, M.C., Mohabbat, M.O., Burzynski, S.R. Preclinical studies of antineoplaston A10 injections.  Drugs Exptl Clin Res 1986;12 (suppl 1):37-45.
  • Burzynski, S.R., Mohabbat, M.O., Lee, S.S.  Preclinical studies of antineoplaston AS2-1 and antineoplaston AS2-5.  Drugs Exptl Clin Res 1986;12 (suppl 1):11-16.
  • Burzynski, S.R. Antineoplaston A3.  Drugs of the Future 1986;11:551-552.
  • Burzynski, S.R. Antineoplastons – History of the research (I).  Drugs Exptl Clin Res 1986;12 (suppl 1):1-9.
  • Burzynski, S.R. Antineoplaston AS2-5.  Annual Drug Data Report 1986;8:319.
  • Burzynski, S.R. Antineoplaston AS2-1.  Annual Drug Data Report 1986;8:320.
  • Burzynski, S.R., Khalid, M. Antineoplaston AS2-5.  Drugs of the Future 1986;11:364-365.
  • Burzynski, S.R. Antineoplaston A10 injections.  Annual Drug Data Report 1986;8:597.
  • Burzynski, S.R. Antineoplaston A3.  Annual Drug Data Report 1986;8:412.
  • Burzynski, S.R. Antineoplaston A2.  Annual Drug Data Report  1986;8:504.
  • Burzynski, S.R., Khalid, M. Antineoplaston AS2-1.  Drugs of the Future 1986; 11: 361-363.
  • Burzynski, S.R. Antineoplaston A2.  Drugs of the Future 1986;11:549-550.
  • Burzynski, S.R. Antineoplaston A5.  Annual Drug Data Report 1986;8:869.
  • Burzynski, S.R. Antineoplaston A5.  Drugs of the Future 1986;11:824-825.
  • Burzynski, S.R. Synthetic antineoplastons and analogs.  Drugs of the Future 1986;11: 679-688.
  • Liau, M.C., Burzynski, S.R. Altered methylation complex isoenzymes as selective targets for cancer chemotherapy.  Drugs Exptl Clin Res 1986;12 (suppl 1):77-86.
  • Lehner, A.F., Burzynski, S.R., Hendry, L.B. 3-phenylacetylamino-2, 6-piperidinedione, a naturally occurring peptide analog with apparent antineoplastic activity may bind to DNA.  Drugs Exptl Clin Res  1986;12 (suppl 1):57-72.
  • Burzynski, S.R., Kubove, E. Toxicology studies of antineoplaston A10 injections in cancer patients.  Drugs Exptl Clin Res 1986;12 (suppl 1):47-55.
  • Burzynski, S.R. Toxicology studies of antineoplaston AS2-5 injections in cancer patients.  Drugs Exptl Clin Res 1986;12 (suppl 1):17-24.
  • Burzynski, S.R., Burzynski, B., Mohabbat, M.O. Toxicology studies of antineoplaston AS2-1            injections in cancer patients.  Drugs Exptl Clin Res 1986;12 (suppl 1):25-35.
  • Lee, S.S., Mohabbat, M.O., Burzynski, S.R. Tissue culture and acute animal toxicity studies of antineoplaston A2.  Future Trends in Chemotherapy 1985;6:481-484.
  • Burzynski, S.R., Hai TT.  Antineoplaston A10.  Drugs of the Future 1985;10:103-105.
  • Burzynski, S.R. Phase I clinical studies of antineoplaston AS2-5 injections.  Recent Advances in Chemotherapy.  Ishigami J. (Ed), University of Tokyo Press. 1985; Tokyo, Japan.
  • Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Toxicology studies on oral formulation of antineoplaston A10 in cancer patients.  Future Trends in Chemotherapy 1985;6:485-493.
  • Burzynski, S.R., Mohabbat MO, Burzynski B. Animal toxicology studies on oral formulation of antineoplaston A10.  Drugs Exptl Clin Res 1984;10:113-118.
  • Lee, S.S., Mohabbat, M.O., Burzynski, S.R. Tissue culture and animal toxicity studies of antineoplaston A2.  Drugs Exptl Clin Res 1984;10:607-610.
  • Burzynski, S.R. Antineoplaston A10.  Annual Drug Data Report 1984;6:124.
  • Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Human toxicology studies on oral formulation of antineoplaston A10.  Drugs Exptl Clin Res 1984;10:891-909.
  • Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Toxicology studies on oral formulation of antineoplaston A10 in cancer patients.  Drugs Exptl Clin Res 1984;10:611-619.
  • Beall, P., Szopa, B., Burzynski, S.R., Hazlewood, C.F. Polypeptides that inhibit human breast cancer cell division.  Cancer Biochem Biophys 1979;3:93-96.
  • Burzynski, S.R.   Przeglad Lekarski 1978;6:583-586.
  • Gross S, Galicka N, Grabarczyk M, Giannini M, Burzynski SR, Stolzmann Z. Urinary peptides inhibit DNA synthesis in vitro in certain cultured neoplastic cells.  Clin Chem 1977;23:148-149.
  • Burzynski, S.R., Stolzmann, Z., Szopa, B., Stolzmann, E., Kaltenberg, O.P. Antineoplaston A in cancer therapy (I).  Physiol Chem Phys 1977;9:485-500.
  • Burzynski, S.R. Antineoplastons: Biochemical defense against cancer.  Physiol Chem Phys 1976;8:275-279.
  • Gross, S., Galicka, N., Burzynski, S.R., Stolzmann, A. Urinary peptides in muscular dystrophy.  Physiol Chem Phys 1976;8:161-166.
  • Burzynski, S.R. Sequential analysis in subnanomolar amounts of peptides; Determination of the structure of a habituation-induced brain peptide (ameletin).  Anal Biochem 1976;70:359-365.
  • Burzynski, S.R., Loo, T.L., Ho, D.H., Rao, P.N., Georgiades, J., Kratzenstein, H. Biologically active peptides in human urine: III.  Inhibitors of the growth of leukemia, osteosarcoma and HeLa cells.  Physiol Chem Phys 1976;8:13-22.
  • Burzynski, S.R., Rao, P.N., Gross, S., Stolzman, Z. Inhibition of the Growth of HeLa Cells by the Peptide Isolated from Normal Human Urine.  Fed Proc 1976;35:623.
  • S.R. Quantitative analysis of amino acids and peptides in the femtomolar range.  Anal Biochem 1975;65:93-99.
  • Burzynski, S.R., Ungar, G. Brain Peptides Associated with Habituation to a Sound Stimulus.  Neuroscience Abstracts 1975;1:329.
  • Ungar, G., Burzynski, S.R., Tate, D.L. Learning-induced Brain Peptides.  Peptides: Chemistry, structure and biology. Walter, R., Meienhofer, J. (Ed),  Ann Arbor Science; 1975; Ann Arbor, Michigan, USA.
  • Burzynski, S.R., Ungar, A.L., Lubanski, E. Biologically active peptides in human urine: II. Effect on intestinal smooth muscle and heart.  Physiol Chem Phys 1974;6:457-468.
  • Burzynski, S.R., Ungar, A.L., Lubanski, E. Effect of Urinary Peptides on Smooth Muscle and Heart.  Fed Proc 1974;33:547.
  • Burzynski, S.R. Biologically active peptides in human urine: I. Isolation of a group of medium-sized peptides.  Physiol Chem Phys 1973;5:437-447.
  • Burzynski, S.R., Georgiades, J. Effect of Urinary  Peptides on DNA, RNA and Protein Synthesis in Normal and Neoplastic Cells.  Fed Proc 1973;32:766.
  • Ungar, G., Burzynski, S.R. Isolation and Purification of a Habituation-inducing Peptide from Trained Rat Brain.  Fed Proc 1973;32:367.
  • Burzynski, S., Czerniak, Z. A simple method for the separation of free and bound amino acids and its application to the identification of bound amino acids in human blood serum.  Chem Anal 1970;15:223-225.
  • Szajner-Milart, J., Burzynski, S.R., Paczos-Chadyma, E., Czerniak, Z. Free amino acids in serum of obese children.  Endokr Pol 1970;21:611-617.
  • Krzeczkowska, I., Czerniak, Z., Burzynski, S. Quantitative determinations of carbohydrates and their statistical analysis, I.  Results obtained in various conditions using paper and thin-layer chromatography.  Chem Anal 1969;13:1221-1228.
  • Burzynski, S. Investigations on unknown ninhydrin-reacting substances in human blood serum I.  Attempts at identification of three such substances.  Experientia 1969;25:490-491.
  • Burzynski, S. Bound amino acids in serum of patients with chronic renal insufficiency.  Clin Chim Acta 1969;25:231-237.
  • Czerniak, Z., Burzynski, S. Free amino acids in serum of patients with chronic renal insufficiency.  Clin Chim Acta 1969;24:367-372.
  • Burzynski, S., Czerniak, Z. A simple method for free and bound amino acid separation.  Folia Soc Sci Lub 1969/70;Sec. A-D 9/10 (suppl):143-144.
  • Burzynski, S., Czerniak, Z. Quantitative determination of amino acids using photometry of             negative printed chromatograms.  Modification of the method and its application for amino acid analysis in blood serum.  Chem Anal 1969;14:667-671.
  • Czerniak, Z., Burzynski, S. Qualitative analysis of amino acids using the multiple development of chromatograms in different eluents.  Chem Anal 1969;14:673-676.
  • Krzeczkowska, I., Czerniak, Z., Burzynski, S. Quantitative determinations of free amino acids in human blood with the use of our own method and Beckman amino acid analyzer.  Pol Arch Med Wewn 1968;40:223-228.
  • Krzeczkowska, I., Czerniak, Z., Burzynski, S. Quantitative determinations of free amino acids in the blood of patients with myocardial infarction using a new method of photometry of the negative printed chromatograms.  Pol Arch Med Wewn 1968;41:361-368.
  • Krzeczkowska, I., Czerniak, Z., Burzynski, S.  Quantitative determinations of carbohydrates and their statistical analysis, II.  Analysis of variance for four-crossed classification and Tukey confidence intervals.  Chem Anal 1968;13:1229-1238.
  • Burzynski, S. Investigations on amino acids and peptides in blood serum of healthy people and patients with chronic renal insufficiency.  1968; Lublin, Poland: 274 pp (doctoral dissertation).
  • Krzeczkowska, I., Burzynski, S. Czerniak Z. Quantitative determination of amino acids using photometry of negative printed chromatograms.  Ann Univ MC Sklodowska 1966;21:125-134.
  • Krzeczkowska, I., Czerniak, Z., Burzynski, S. The application of the negative printed chromatograms for quantitative determination of free amino acids in the blood of healthy people.  Ann Univ MC Sklodowska 1966;21:313-322.
  • Krzeczkowska, I., Burzynski, S., Czerniak, Z. Investigations on the possibility of the determination of mushroom species on the basis of the composition of their amino acids.  Ann Univ MC Sklodowska 1965;20:221-229.
  • Krzeczkowska, I., Czerniak, Z., Burzynski, S. Free and bound amino acids of some edible mushrooms.  Ann Univ MC Sklodowska 1965;20:303-312.
  • Krzeczkowska, I., Czerniak, Z., Burzynski, S. Bound amino acids of some edible mushrooms.  Ann Univ MC Sklodowska 1964;19:329-336.
  • Krzeczkowska, I., Burzynski, S., Czerniak, Z. Free amino acids of some edible mushrooms.  Ann Univ MC Sklodowska 1964;19:321-328.

 

SELECTED ABSTRACTS OF PRESENTATIONS

BY S.R. BURZYNSKI AND ASSOCIATES

 

  • Burzynski, S.R. Current innovations in cancer treatment.  War on cancer, Texas chapter.  Presented at The Truth About Cancer LIVE; October 5, 2017 – October 7, 2017; Orlando, FL.
  • Burzynski, S.R. Precision therapy of glioblastoma.  Presented at BIT’s 8th Annual World Congress of NeuroTalk-2017; May 22, 2017 – May 24, 2017; Barcelona, Spain.
  • Burzynski, S.R., Janicki, T., Burzynski, G. Treatment of children with primary CNS tumors and leptomeningeal, disseminated and/or multicentric disease in phase II studies with antineoplastons A10 and AS2-1.  Presented at the 18th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 12, 2016 – June 15, 2016; Liverpool, U.K.
  • Burzynski, S.R., Janicki, T., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors based on protocol BT-22. CT-004.  Presented at the 16th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 28, 2014 – July 2, 2014; Singapore.
  • Burzynski, G., Janicki, T., Burzynski, S.R., Marszalek, A. Long-term survival (over 20 years) and pathologically confirmed complete response in pediatric anaplastic astrocytoma: a case report. HG-017.  Presented at the 16th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 28, 2014 – July 2, 2014; Singapore.
  • Janicki, T., Burzynski, S.R., Burzynski, G., Marszalek, A. Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma (PNET) without recurrence: a case report. MB-039-020.  Presented at the 16th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 28, 2014 – July 2, 2014; Singapore.
  • Burzynski, G., Burzynski, S.R., Janicki, T., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme based on protocol BT-21.  Presented at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology in conjunction with the 18th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology; November 21-24, 2013; San Francisco, California, USA.
  • Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in pediatric recurrent diffuse intrinsic pontine glioma.  Presented at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology in conjunction with the 18th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology; November 21-24, 2013; San Francisco, California, USA.
  • Janicki, T., Burzynski, S., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 (ANP) in children with high-grade glioma (Protocol BT-06).  Presented at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology in conjunction with the 18th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology; November 21-24, 2013; San Francisco, California, USA.
  • Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. Long-term survival (over 13 years) in a child with recurrent diffuse pontine gliosarcoma: A case report.  Presented at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology in conjunction with the 18th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology; November 21-24, 2013; San Francisco, California, USA.
  • Burzynski, S.R. Molecular profiling in oncology practice: The results of treatment in a group of 1,633 patients.”  Presented at BIT’s 4th Annual World Cancer Congress – 2011; May 22-25, 2011; Dalian, China.
  • Burzynski, S.R, Weaver, R.A., Janicki, T.J., Burzynski, G.S., Szymkowski, B., Acelar, S.S. OT-15. Preliminary results of a phase II study of antineoplastons A10 and AS2-1 (ANP) in adult patients with recurrent mixed gliomas.  Presented at the 15th Annual Scientific Meeting of the Society for Neuro-Oncology; November 16-22, 2010; Montreal, Quebec, Canada.
  • Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K. CB-15. Targeting microRNAs in glioma cells with antineoplastons.  Presented at the 15th Annual Scientific Meeting of the Society for Neuro-Oncology; November 16-22, 2010; Montreal, Quebec, Canada.
  • Burzynski, S.R, Weaver, R.A., Janicki, T., E, Szymkowski, B., Acelar, S.S., Burzynski, G.S. A phase II study of antineoplaston A10 and AS2-1 injections in children with low-grade astrocytomas.  Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna, Austria.
  • Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K. Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells.  Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna, Austria.
  • Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B., Burzynski, G.S. Phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.  Protocol BC-BT-11.  Presented at the 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with the 6th Meeting of the Asian Society for Neuro-Oncology; May 11-14, 2009; Yokohama, Japan.
  • Weaver, R.A., Szymkowski, B., Burzynski, S.R. Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP).  Presented at the 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with the 6th Meeting of the Asian Society for Neuro-Oncology; May 11-14, 2009; Yokohama, Japan.
  • Patil, S., Burzynski, S.R., Chittur, S., Mrowczynski, E., Grela, K. Antineoplastons inhibit MCM complex in glioblastoma cells.  Presented at the 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with the 6th Meeting of the Asian Society for Neuro-Oncology; May 11-14, 2009; Yokohama, Japan.
  • Burzynski, S.R. New research on molecular mechanisms and prevention of Alzheimer’s disease.  Presented at the 17th Annual world Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies, Spring 2009 Session; April 21-April 25, 2009; Orlando, Florida.
  • Burzynski, S. Life extension through application of chromatin remodeling agents.  Presented at the 7th Anti-Aging Medicine World Congress & Medispa; March 19-March 21, 2009; Monte-Carlo, Monaco.
  • Marquis, A., Kubove, E., Walczak, M., Burzynski, S. Hepatocellular carcinoma, recurrent after standard therapy, successfully treated with a combination of targeted therapies.  Presented at the 20th International Congress on Anti-Cancer Treatment; February 3-February 6, 2009; Paris, France.
  • Weaver, R., De Leon, L., Burzynski, S. A complete response in a patient with inoperable adenocarcinoma of the head of the pancreas treated with a combination of gene-targeted therapies.  Presented at the 20th International Congress on Anti-Cancer Treatment; February 3-February 6, 2009; Paris, France.
  • Burzynski, S.R. The Coming Pandemic of Liver Cancer.  In Search of Genomic Solutions.  Presented at the 16th Annual World Congress of A4M, Winter 2008 Session; December 12-December 15, 2008; Las Vegas, Nevada.
  • Burzynski, S.R., Weaver, R., Janicki, T., Szymkowski, B., Samuel, S., Burzynski, G. Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma: A preliminary report.  Presented at the 13th Annual Scientific Meeting of the Society for Neuro-Oncology; November 20-November 23, 2008; Las Vegas, Nevada.
  • Burzynski, S.R., Patil, S., Chittur, S., Mrowczynski, E., Grela, K. Antineoplaston AS2-1 affects cell cycle checkpoints leading to apoptosis in human glioblastoma cells.  Presented at the 13th Annual Scientific Meeting of the Society for Neuro-Oncology; November 20-November 23, 2008; Las Vegas, Nevada.
  • Burzynski, S.R., Patil, S., Ilkowska-Musial, E., Chittur, S., Gupta, V., Sarangi, R. Pathway analysis of the effect of chromatin remodeling agent phenylbutyrate on the brains of honeybees.  Presented at Neuroscience 2008; November 15-November 19, 2008; Washington D.C.
  • Burzynski, S.R. Practical Application of Gene Silencing Theory of Aging.  Life Extension in Animals and Human Clinical Trials.  Presented at the Dubai Congress on Anti-Aging and Aesthetic Medicine (DCAAAM); November 7-November 9, 2008; Dubai.
  • Burzynski, S.R. Antineoplastons and Targeted Gene Therapy.  Presented at ACAM Scientific Conference; October 15-October 19, 2008; Las Vegas, Nevada.
  • Burzynski, S.R., Weaver, R., Janicki, T., Szymkowski, B., Walczak, M., Burzynski, G. Phase II study of antineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma.  Presented at the European Association for NeuroOncology (EANO); September 12-September 14, 2008; Barcelona, Spain.
  • Patil, S., Burzynski, S.R., Chittur, E., Mrowczynski, K.G. The ingredients of antineoplaston AS2-1 down-regulate glycolysis pathways in glioblastoma cells.  Presented at the European Association for NeuroOncology (EANO); September 12-September 14, 2008; Barcelona, Spain.
  • Burzynski, S.R. Practical application of gene silencing theory of aging.  Life extension in animal testing and human clinical trials.  Presented at the European Congress on Anti-Aging & Aesthetic Medicine (ECAAAM); September 11-September 14, 2008; Düsseldorf, Germany.
  • Burzynski, S.R., Weaver, R., Janicki, T., Walczak, M., Szymkowski, B., Samuel, S. Phase II study of antineoplastons A10 and AS2-1 (ANP) in children with optic pathway glioma: A preliminary report.  Presented at the 13th International Symposium on Pediatric Neuro-Oncology; June 29-July 2, 2008; Chicago, Illinois.
  • Burzynski, S.R. Genome, Epigenome and Aging. Presented at the First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies; May 29-31, 2008; Estoril, Portugal.
  • Burzynski, S.R. Personalized Cancer Treatment in Genomics Era. Presented at the First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies; May 29-31, 2008; Estoril, Portugal.
  • Burzynski, S.R. Practical application of gene silencing theory of aging. Life extension in animals and human clinical trials.  Presented at the 16th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies; April 25-27, 2008; Orlando, Florida.
  • Burzynski, S.R. Antineoplaston peptides in treating cancer.  Presented at the 2008 Orthomolecular Health-Medicine conference; February 29-March 2, 2008;  San Francisco, California.
  • Burzynski, S.R. Anti-Aging peptides—a new frontier in healing.  Presented at the 2008 Orthomolecular Health-Medicine conference; February 29-March 2, 2008;  San Francisco, California.
  • Burzynski, S.R. Genomic approach to cancer treatment.  Presented at the 15th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies; December 12-15, 2007; Las Vegas, Nevada.
  • Burzynski, S.R. Genomics in Cancer Treatment.  Presented at the 1st Annual India Conference on Anti-Aging and Regenerative Medicine; November 16-18, 2007; Mumbai, India.
  • Burzynski, S.R. Epigenomic Approach to Anti-Aging.  Presented at the 1st Annual India Conference on Anti-Aging and Regenerative Medicine; November 16-18, 2007; Mumbai, India.
  • Burzynski, S.R., Weaver, R.A., Szymkowski, B. A case report of a complete response and 20-year survival of a patient with a recurrent, diffuse, intrinsic brainstem anaplastic astrocytoma.  Presented at the Society for Neuro-Oncology 12th Annual Scientific Meeting; November 15-18, 2007; Dallas, Texas.
  • Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. Phenylacetylglutamine (PG) and phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells.  Presented at the Society for Neuro-Oncology 12th Annual Scientific Meeting; November 15-18, 2007; Dallas, Texas.
  • Burzynski, S.R., Tempczyk-Russell, A., Ilkowska-Musial, E. Amyloid precursor protein (APP) and related protein fragmentation in consolidation of memory. Presented at Neuroscience 2007, the Society’s Annual Meeting; November 3-7, 2007; Sand Diego, California.
  • Burzynski, S.R. Epigenomic approach to anti-aging.  Presented at: 4th Congresso Internacional de Antienvelhecimento; October 26-27, 2007; Sao Paulo, Brazil.
  • Burzynski, S.R. Nutrition and ageing : Gene silencing or gene activation.  Presented at: 10th European Nutrition Conference; July 10-13, 2007; Paris, France.
  • Burzynski, S.R. La solution génétique contre le vieillissement.  Presented at: Anti-Aging Medicine World Congress; March 22-24, 2007; Monte Carlo.
  • Burzynski, S.R.  Genetics of Brain Aging (II).  Genetic Mechanisms in Encoding and Consolidation of Memory.  Presented at: 14th Annual International Congress on Anti-Aging Medicine; December 7-10, 2006; Las Vegas, Nevada.
  • Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.J., Khan, M.I., Dolgopolov, V. Treatment of multicentric brainstem gliomas with Antineoplastons (ANP) A10 and AS2-1.  Presented at the Society for Neuro-Oncology’s 11th Annual Meeting; November 16-19, 2006; Orlando, Florida.
  • Burzynski, S.R., Christensen, R., Ilkowska-Musial, E. Memory processing proteins have common amino acid sequences with Scotophobin.  Presented at: Neuroscience 2006, the Society’s 36th annual meeting; October 14-18, 2006; Atlanta, Georgia.
  • Burzynski, S.R., Weaver, R.A., Janicki, T.J., Szymkowski, B., Jurida, G.F. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in adult patients with diffuse intrinsic brainstem gliomas.  Presented at: The European Association for Neuro Oncology: 7th Congress Vienna Hofburg Congress Center; September 14-17, 2006; Vienna, Austria.
  • Burzynski, S.R. Genetics of Brain Aging (I).  Gene Silencing in Neurons.  Presented at: 14th Annual International Congress on Anti-Aging Medicine; July 14-16, 2006; Chicago, Illinois.
  • Burzynski, S.R. The Genetic Solution for Anti-Aging.  Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.
  • Burzynski, S.R. The Genetic Solution for Anti-Aging.  Workshop (III) Aminocare Products and Aging of the Brain.  Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.
  • Burzynski, S.R. The Genetic Solution for Anti-Aging.  Workshop (II) Aminocare Products and Skin Aging.  Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.
  • Burzynski, S.R. The Genetic Solution for Anti-Aging.  Workshop (I) Theory and Age-Management with Aminocare Products.  Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan
  • Burzynski, S.R. Gene Silencing Theory of Aging.  Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.
  • Burzynski, S.R., Weaver, R.A., Janicki, T.J., Jurida, G.F., Szymkowski, B.G., Kubove, E. Phase II studies of Antineoplastons A10 and AS2-1 (ANP) in children with newly diagnosed diffuse, intrinsic brainstem gliomas.  Presented at: 12th International Symposium on Pediatric Neuro-Oncology; June 6-9, 2006; Nara, Japan.
  • Burzynski, S.R. Chronobiology of Aging.  Presented at: International Danube Symposium for Neurological Sciences and Continuing Education; May 10-13, 2006; Kazimierz Dolny, Poland.
  • Burzynski, S.R. The Genetic Solution for Anti-Aging.  Presented at: 14th International Congress on Anti-Aging Medicine; April 7-9, 2006; Orlando, Florida.
  • Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.G., Jurida, G.F. Burzynski, B. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in patients with recurrent, diffuse intrinsic brain stem gliomas.  Presented at the 17th International Congress on Anti-Cancer Treatment; January 30-February 2, 2006; Paris, France.
  • Burzynski, S.R. Master Clock of Life (II). How to Turn the Clock Back.  Presented at: XIII International Congres on Anti-Aging Medicine; December 8-12, 2005; Las Vegas, Nevada.
  • Burzynski, S.R. Master Clock of Life (I) “Junk DNA” and Promotors Region as Major Components of the Clock.  Presented at: XIII International Congres of Anti-Aging Medicine; August 19-21, 2005; Chicago, Illinois.
  • Burzynski, S.R., Weaver, R.A., Janicki, T.J., Burzynski, B., Jurida, G. Targeted therapy with ANP in children less than 4 years old with inoperable brain stem gliomas.  Presented at: 2nd Quadrennial meeting of the World Federation of Neuro-Oncology/ 6th meeting of the European Association of NeuroOncology; May 5-8, 2005; Edinburgh, Scotland, UK.
  • Weaver, R.A., Burzynski, S.R., Janicki, T.J., Burzynski, B., Jurida, G., Szymkowski, B. Long-term survival in patients with glioblastoma multiforme treated in phase II studies with ANP.  Presented at: 2nd Quadrennial meeting of the World Federation of Neuro-Oncology/ 6th meeting of the European Association of NeuroOncology; May 5-8, 2005; Edinburgh, Scotland, UK.
  • Burzynski, S.R., Janicki, T.J., Weaver, R.A., Burzynski, B. Targeted therapy with Antineoplastons A10 and AS2-1 (ANP) of high grade, recurrent and progressive brain stem glioma.  Presented at the 16th International Congress on Anti-Cancer Treatment; February 1-4, 2005; Paris, France.
  • Burzynski, S.R.   Presented at: The Cleveland Clinic Neuro-Oncology 2005: Current Concepts; January 29-31, 2005; Lake Buena Vista, FL, USA.
  • Burzynski, S.R., Jacquet, A., Moore, N., Musial, L. Gene silencing theory of aging: the clinical trial supporting the theory.  Presented at: American Academy of Anti-Aging Medicine (A4M) Conference on Anti-Aging Medicine, December 2-5, 2004; Las Vegas, USA.
  • Burzynski, S.R., Weaver, R. Bestak. , Lewy, R.I., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.  Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma.  Presented at: 9th Annual Meeting Society for Neuro-Oncology, November 18-21, 2004; Toronto, Canada.
  • Weaver, R.A., Burzynski, S.R., Bestak, M., Lewy, R.I., Janicki, T.J., Szymkowski, B., Jurida, G., Khan, M.I., Dolgopolov, V. Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme.  Presented at: 9th Annual Meeting Society for Neuro-Oncology, November 18-21, 2004; Toronto, Canada.
  • Burzynski, S.R., Janicki, T., Weaver, R., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V. Clinical application of body epigenetic system. Multi-targeted therapy for primary brain tumors.              Presented at World Conference on Magic Bullets Celebrating Paul Ehrlich’s 150th Birthday; September, 2004; Nurnberg, Germany.
  • Burzynski, S.R. The new generation of food supplements effecting gene expression.  Presented at 2nd Congress Food, Nutrition and Health in Poland Integrated with European Union; June 23-26, 2004; Warsaw, Poland.
  • Burzynski, S.R., Weaver, R.A., Bestak, M., Janicki, T.J, Szymkowski, B., Jurida G., Khan, M., Dolgopolov, V.  Treatment of Primitive Neuroectodermal Tumors (PNET) with Antineoplastons A10 and AS2-1 (ANP). Preliminary Results of Phase II Studies.  Presented at 11th International Symposium on Pediatric Nuero-Oncology; June 13-16, 2004; Boston, MA.
  • Burzynski, S.R., Weaver, R.A., Bestak, M., Janicki, T.J, Jurida G., Szymkowski, B., Khan, M., Dolgopolov, V. Phase II Studies of Antineoplastons A10 and AS2-1 (ANP) in Children with Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System. A Preliminary Report.  Presented at 11th International Symposium on Pediatric Neuro-Oncology; June 13-16, 2004; Boston, MA.
  • Burzynski, S.R., Lewy, R.I., Axler, M., Janicki, T.J. Treatment of Malignant Mesothelioma (MM) with Sodium Phenylbutyrate.  Presented at the 15th International Congress on Anti-Cancer Treatment; February 9-12, 2004, Paris, France.
  • Waldbillig, R.J., Mrowczynski, E., Burzynski, S.R. Phenylacetic acid (PN) and Phenylacetylglutamine (PG): Mechanism of Uptake and changes in Epigenetic-Mechanisms Regulating Gene Expression.  Presented at the 2nd Annual American Association for Cancer Research (AACR) International Conference; October 26-30, 2003, Phoenix, AZ.
  • Burzynski, S.R. Interaction of antineoplastons with genome in cancer and aging.  Presented at: Annual Meeting of International Academy of Oral Medicine and Toxicology; September 12-13, 2003, New Orleans, Louisiana.
  • Burzynski, S.R. Antineoplastons in: Cancer Treatment and Age Management Therapy.  Presented at American Collage for Advancement in Medicine (ACAM); May 16, 2003, Washington, DC.
  • Burzynski, S.R. The State of Antineoplaston Research – Spring of 2003.  Presented at the 5th Annual Comprehensive Cancer Care Conference; April 11, 2003, Washington, DC.
  • Waldbillig, R.J., Burzynski, S.R. The application of chromatography to the pharmacokinetic study of Antineoplastons A10 and AS2-1.  Presented at the 3rd International Symposium of Chromatography and Natural Products; June 12-15, 2002, Lublin, Poland.
  • Burzynski, S.R.   Presented at ‘Health-Trends 2000’, The 2nd International Conference; August 27-29, 1999, Copenhagen, Denmark.
  • Burzynski, S.R. Phase II Trial of Antineoplaston A10 and AS2-1 in Brain Stem Glioma.  Presented at International Conference on Integrative Medicine; May 1, 1999, Seattle, Washington, USA.
  • Czerwinski, A., Klimczak, M.W., Burzynski, S.R. Enancjoselektywna analiza skladnikow Antyneoplastonu A10 metoda HPLC.  Presented at the XVII Naukowy Zjazd Polskiego Towarzystwa Farmaceutycznego, September 1998, Krakow, Poland.
  • Burzynski, S.R. Gene Therapy with Antineoplastons.  Presented at Comprehensive Cancer Care; June, 1998, Washington, D.C., USA.
  • Burzynski, S.R. Antineoplastons in the Treatment of Malignant Brain Tumors.  Presented at 5th International Conference of Anti-Aging Medicine and Biomedical Technology; December, 1997, Las Vegas, Nevada, USA.
  • Burzynski, S.R. New Concepts in Innovative Cancer Therapies.  Presented at 4th Annual Conference on Anti-Aging Medicine and Biomedical Technology; Dec., 1996, Las Vegas, Nevada, USA.
  • Burzynski, S.R. Antineoplastons Today.  Presented at the First International Congress On Alternative & Complementary Medicine; May, 1995; Washington, DC, USA.
  • Soltysiak-Pawluczuk, D., Burzynski, S.R. Uptake Characteristics of Antineoplaston AS2-1 by Human Hepatoma Cells.  Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.
  • Lee, S.S., Burzynski, S.R. Synergistic Inhibitory Effect of Antineoplaston A5 and Thymidine on the Growth of Human Cancer Cell Lines.  Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.
  • Liau, M.C., Liau, C.P., Burzynski, S.R. Helper Inducers of Terminal Differentiation.  Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.
  • Burzynski, S.R., Szymkowski, B., Kubove, E. Phase II Clinical Trials of Antineoplaston AS2-1 in Asymptomatic HIV Infection.  Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.
  • Burzynski, S.R., Kubove, E., Szymkowski, B. Phase II Clinical Trials of Antineoplaston A10 and AS2-1 Infusions in High Grade Glioma.  Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.
  • Kleinrok, Z., Burzynski, S.R., Juszkiewicz, M., Chodkowska, A., Feldo, M. The Influence of Antineoplaston A5 on the Central Dopaminergic Structures.  Presented at: 11th Congress of the Polish Pharmacological Society; September, 1992; Gdansk, Poland.
  • Burzynski, S.R., Kubove, E., Szymkowski, B., Burzynski, B. Phase II Clinical Trials of Novel Differentiation Inducer – Antineoplaston AS2-1 in AIDS and Asymptomatic HIV Infection.  VIII International Conference on AIDS/III STD World Congress; July, 1992; Amsterdam, The Netherlands.
  • Burzynski, S.R. Differentiation Inducers-Possible Agents for Cancer Therapy in Pregnancy.  Presented at the World Congress of Prenatal and Perinatal Psychology and Medicine; May, 1992; Krakow, Poland.
  • Burzynski, S.R., Kubove, E., Burzynski, B. Phase II Clinical Trials of Antineoplaston A10 and AS2-1 Infusions in Astrocytoma.  Presented at the 17th International Congress of Chemotherapy; June, 1991; Berlin, Germany.
  • Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R. Prevention of Drug-Induced DNA Hypermethylation by Antineoplastons.  Presented at the 17th International Congress of Chemotherapy; June, 1991; Berlin, Germany.
  • Lee, S.S., Burzynski, S.R. Synergistic Effect of Antineoplaston A5 and Retinoic Acid on the Induction of Human Promyelocytic Leukemia line HL-60.  Presented at the 17th International Congress of Chemotherapy; June, 1991; Berlin, Germany.
  • Liau, M.C., Lee, S.S., Liau, C.P., Burzynski, S.R. Efficient Methylation when Locked in Place Becomes a Major Problem of Cancer.  Presented at the 82nd Annual Meeting of the American Association for Cancer Research, May, 1991, Houston, Texas, USA.
  • Burzynski, S.R.   Presented at: The World Research Foundation Congress, October 7, 1990, Los Angeles, CA, USA.
  • Ashraf, A.Q., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic Study of Radioactive Antineoplaston AS2-1 Following Oral Administration in Rats.  Presented at the 9th International Symposium on Future Trends in Chemotherapy, March, 1990, Geneva, Switzerland.
  • Burzynski, S.R., Kubove, E., Burzynski, B. Treatment of Hormonally Refractory Cancer of the Prostate with Antineoplaston AS2-1.  Presented at the 9th International Symposium on Future Trends in Chemotherapy, March, 1990, Geneva, Switzerland.
  • Liau, M.C., Lee, S.S., Burzynski, S.R. Abnormal Methylation Enzymes as Selective Targets of Cancer Therapy.  Presented at the 42nd Annual Symposium on Fundamental Cancer Research, M.D. Anderson Hospital and Tumor Institute; October, 1989; Houston, Texas, USA.
  • Liau, M.C., Lee, S.S., Burzynski, S.R. Hypomethylation of Nucleic Acids: A Key to the Induction of Terminal Differentiation.  Presented at the 10th Congress of the Polish Pharmacological Society, September, 1989, Bialystok, Poland.
  • Burzynski, S.R. Antineoplastons – New Way for Cancer Chemotherapy.  Presented at the 10th Congress of the Polish Pharmacological Society, September, 1989, Bialystok, Poland.
  • Liau, M.C., Lee, S.S., Burzynski, S.R. Role of Methylation Enzymes in Directing Phenotypic Changes.  Presented at the 41st Annual Symposium on Fundamental Cancer Research.  D. Anderson Hospital and Tumor Institute; October, 1988; Houston, Texas, USA.
  • Liau, M.C., Khalid, M., Burzynski, S.R. Differentiation Inducing Factors of Antineoplaston A5.  Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.
  • Khalid, M., Burzynski, S.R. Phenylacetylglutamine Derivatives as Novel Chemotherapeutic Agents.  Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.
  • Lee, S. S., Burzynski, S.R. Terminal Differentiation of HL-60 Human Promyelocytic Leukemia Cells Induced by Antineoplaston A2.  Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.
  • Ashraf, A.Q., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic Analysis of Antineoplaston A10 Injections Following Intravenous Administration in Rats.  Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.
  • Burzynski, S.R. Treatment of Malignant Brain Tumors with Antineoplastons.  Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.
  • Liau, M.C., Lee, S.S., Burzynski, S.R. Modulation of Tumor Methylation Complex Isozymes as a Decisive Factor in the Induction of Differentiation by Antineoplaston A5.  Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing; November, 1987; Madrid, Spain.
  • Lee, S.S., Burzynski, S.R. Induction of Differentiation of HL-60 Human Promyelocytic Leukemic Cells by Antineoplaston A5.  Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing; November, 1987; Madrid, Spain.
  • Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Protective Effect of Antineoplaston A10 in Hepatocarcinogenesis Induced by Aflatoxin B 1.  Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing; November, 1987; Madrid, Spain.
  • Burzynski, S.R., Kubove, E., Burzynski, B. Phase I Clinical Studies of Oral Formulation of Antineoplaston A3.  Presented at the 10th International Congress of Pharmacology, August, 1987, Sydney, Australia.
  • Liau, M.C., Ashraf, A.Q., Burzynski, S.R. Active Anticancer Components of Antineoplaston Formulations.  Presented at the 10th International Congress of Pharmacology, August, 1987, Sydney, Australia.
  • Ashraf, A.Q., Burzynski, S.R. Comparative Study of Antineoplaston A10 Levels in Plasma of Healthy People and Cancer Patients.  Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.
  • Burzynski, S.R. Treatment of Bladder Cancer with Antineoplaston Formulations.  Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.
  • Burzynski, S.R. Antineoplastons: Basic Research and Clinical Applications.  Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.
  • Burzynski, S.R. Modeling Studies Suggest the Modified Dipeptide Analog Phenylacetylamino-2, 6-piperidinedione May Interact with DNA.  Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.
  • Burzynski, S.R., Kubove, E., Burzynski, B. Phase I Clinical Studies of Oral Formulation of Antineoplaston AS2-1.  Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.
  • Lee, S.S., Burzynski, S.R. A Unique Pattern of Growth Inhibition by Antineoplaston A5 on a T-Leukemia Cell Line.  Presented at the 14th Annual meeting of the International Society of Oncodevelopmental Biology and Medicine; August, 1986; Helsinki, Finland.
  • Liau, M.C., Kampalath, B.N., Szopa, M., Burzynski, B., Burzynski, S.R. Chemo-surveillance: A Novel Concept on the Natural Defense Mechanism Against Cancer.  Presented at the 14th Annual meeting of the International Society of Oncodevelopmental Biology and Medicine; August, 1986; Helsinki, Finland.
  • Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Chemoprevention by Antineoplaston A10 on Benzo (1) pyrene Induced Pulmonary Neoplasia.  Presented at the 5th Mediterranean Congress of Chemotherapy; October, 1986; Cairo, Egypt.
  • Burzynski, S.R., Kubove, E. Phase I Clinical Studies of Antineoplaston A2 Injections.  Presented at the 14th International Cancer Congress; August, 1986; Budapest, Hungary.
  • Hendry, L.B., Lehner, A.F., Muldoon, T.G., Copland, J.A., Mahesh, V.B., Mills, T.M., Burzynski, S.R. Investigations of the Mode of Action of Antineoplaston A10: Evidence for Binding to DNA.  Presented at the 14th International Cancer Congress; August, 1986; Budapest, Hungary.
  • Burzynski, S.R., Kubove, E., Burzynski, B. Phase I Clinical Studies of Antineoplaston A5 Injections.  Presented at the III World Conference on Clinical Pharmacology and Therapeutics; July, 1986; Stockholm, Sweden.
  • Burzynski, S.R., Kubove, E. Phase I Clinical Studies of Antineoplaston A3 Injections.  Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.
  • Khalid, M., Burzynski, S.R. N,N’-disubstituted L-isoglutamines as Novel Cancer Chemotherapeutic Agents.  Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.
  • Lee, S.S., Mohabbat, M.O., Burzynski, S.R. In Vitro Cancer Growth Inhibition and Acute Animal Toxicity Studies of Antineoplaston A3.  Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.
  • Lehner, A.F., Copland, J.A., Muldoon, T.G., Burzynski, S.R., Hendry, L.B. In Vitro Studies of the Stereospecificity of Antineoplaston A10 Interaction with Double-stranded DNA.  Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.
  • Ashraf, A.Q., Kampalath, B.N., Liau, M.C., Burzynski, S.R. Pharmacokinetic Study of Radioactive Antineoplaston A10 Following Oral Administration in Rats.  Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.
  • Hendry, L.B., Muldoon, T.G., Burzynski, S.R., Copland, J.A., Lehner, A.F. Stereochemical Modeling Studies of the Interaction of Antineoplaston A10 with DNA.  Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.
  • Burzynski, S.R., Kubove, E. Phase I Clinical Studies of Antineoplaston Al 0 Injections.  Presented at the 2nd Biennial Conference of Indian Society of Oncology; February, 1986; Bombay, India.
  • Burzynski, S.R., Lehner, A.F., Hendry, L.B. Putative Mechanism of Action of a Novel Peptide Analog with Apparent Antineoplastic Activity: Stereospecific interaction with DNA.  Presented at the 13th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine; September, 1985; Paris, France.
  • Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R. Quantitative Assay of Plasma and Urinary Peptides as Aid for Evaluation of Cancer Patients Undergoing Antineoplaston Therapy.  Presented at the 13th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine; September, 1985; Paris, France.
  • Hendry, L.B. Lehner, A.F., Burzynski, S.R. A Novel Naturally-occurring Peptide Analog with Apparent Antineoplastic Activity May Interact with DNA.  Presented at the International Symposium, Cancer: Perspective for Control; August, 1985; Beijing, China.
  • Hendry, L.B., Lehner, A.F., Burzynski, S.R. Spectroscopic Studies of the Interaction of Antineoplaston A10 with DNA.  Presented at the 12th Symposium of the International Association for Comparative Research on Leukemia and Related Disease; July, 1985; Hamburg, Germany.
  • Burzynski, S.R. Phase I Clinical Studies of Antineoplaston AS2-5 Injections.  Presented at the 14th International Congress of Chemotherapy; June, 1985; Kyoto, Japan.
  • Burzynski, S.R., Burzynski, B., Mohabbat, M.O. Phase I Clinical Studies of Antineoplaston AS2-1 Injection.  Presented at the 3rd European Conference on Clinical Oncology and Cancer Nursing; June, 1985; Stockholm, Sweden.
  • Liau, M.C., Burzynski, S.R. Alteration of Methylation Complex of  Isoenzymes Critical to Malignant Evolution.  Presented at the 12th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine, October, 1984; Houston, USA.
  • Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Toxicology Studies of Oral Formulation of Antineoplaston A10 in Cancer Patients.  Presented at the 6th International Symposium on Future Trends in Chemotherapy; May, 1984; Pisa, Italy.
  • Lee, S. S., Mohabbat, M.O., Burzynski, S.R. Tissue Culture and Animal Toxicity Studies of Antineoplaston A2.  Presented at the 6th International Symposium on Future Trends in Chemotherapy; May, 1984; Pisa, Italy.
  • Burzynski, S.R., Hendry, L.B., Mohabbat, M.O., Liau, M.C., Khalid, M., Burzynski, B. Purification, Structure Determination, Synthesis and Animal Toxicity Studies of Antineoplaston A10; PS 12.4.11-4.  Presented at the 13th International Congress on Chemotherapy, TOM 17; August, 1983; Vienna, Austria.
  • Burzynski, S.R. Recent Advances in Ultramicroanalysis of Biologically Active Peptides.  Presented at the 30th Southwest Regional American Chemical Society meeting, 1974; Houston, Texas.
  • Ungar, G., Burzynski, S.R. Detection of a Behavior-inducing Peptide (Scotophobin) in Brain by Ultramicroanalytical Method.  Fed Proc., 1972; 31: 398.
  • Burzynski, S.R., Czerniak, Z. The Photometry of Negative Printed Chromatograms and its Application for Amino Acid Analysis in Human Blood.  Biuletyn VII Ogolnopolskiej Konferencji Studenckich Kol Naukowych Akademii Medycznych; 1966; Poznan, Poland.

 

PATENTS

                  Patent No.     National          Country                     Title

Patent No.

AIDS

638869                                   Australia                        Pharmaceutical compositions for use in treating AIDS.

0500905        ATE135,217     Austria                           Pharmaceutical compositions for use in treating AIDS.

0500905                                 Belgium                         Pharmaceutical compositions for use in treating AIDS.

                  0500905                                 Denmark                       Pharmaceutical compositions for use in treating AIDS.

0500905                                 Europe                          Pharmaceutical compositions for use in treating AIDS.

                  0500905                                 France                           Pharmaceutical compositions for use in treating AIDS.

0500905        69117923         Germany                       Pharmaceutical compositions for use in treating AIDS.

0500905        3019970           Greece                          Pharmaceutical compositions for use in treating AIDS.

0500905                                 Italy                                Pharmaceutical compositions for use in treating AIDS.

0500905                                 Luxembourg                  Pharmaceutical compositions for use in treating AIDS.

0500905                                 Netherlands                  Pharmaceutical compositions for use in treating AIDS.

28633                                     Philippines                    Methods for treating AIDS.

81889                                     Singapore                     Pharmaceutical compositions for use in treating AIDS.

91/6977                                  South Africa                  Pharmaceutical compositions for use in treating AIDS.

0500905                                 Spain                             Pharmaceutical compositions for use in treating AIDS.

0500905                                 Sweden                         Pharmaceutical compositions for use in treating AIDS.

0500905                                 Switzerland                   Pharmaceutical compositions for use in treating AIDS.

                  0500905                                 United Kingdom            Pharmaceutical compositions for use in treating AIDS.

5089508                                 USA                               Methods for treating AIDS.

5254587                                 USA                               Methods for treating AIDS.

Aminocare

  Pending       181/2004          Arab Emirates                Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  2002352843                           Australia                        Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  Pending       PI0214430-1     Brazil                             Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

2468133                                 Canada                         Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

ZL02823606.8                  China                     Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

                  Patent No.     National          Country                     Title

Patent No.

  009516                           Eurasia                    Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

The Eurasian patent has been validated in the following contracting countries: Azerbaijan (AZ), Kazahstan (KZ), and Russia (RU).

  1450781                         Europe                    Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  1450781                         France                    Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  1450781    DE60212393T2    Germany                       Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  Pending       P04-02240        Hungary                        Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

212246                           India                       Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  ID0018257                              Indonesia                      Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  1450781                                 Ireland                           Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  162141                                   Israel                             Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  4614660                                 Japan                            Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

247856                           Mexico                    Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

532833                           New Zealand             Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  332858                                   Norway                          Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  1-2004-500758                       Philippines                    Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  953483                                   Republic of Korea         Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  121173                                   Romania                       Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  104603                                   Singapore                     Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

21542                            Slovenia                  Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  2004/4115                              South Africa                  Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

  78977                                     Ukraine                         Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

                  7427619132                           USA                               Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

                  Patent No.     National          Country                     Title

Patent No.

Atherosclerosis and Restenosis

757114                           Australia                  Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

  1171110                         Austria                    Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

  1171110                         Belgium                   Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

2345409                         Canada                   Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

  1171110                         Europe                    Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

69916330T2                    France                    Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

1117110    69916330T2       Germany                 Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

1045253                         Hong Kong               Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

  1171110                         Ireland                    Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

  1171110                         Italy                        Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

                  4536258                         Japan                     Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

  1171110                         Luxembourg              Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

  1171110                         Netherlands              Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

1171110    2219102               Spain                             Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

  1171110                         Switzerland               Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

  1171110                         United Kingdom         Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

                  6127419                         USA                        Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

Autoimmune disease

656484                                   Australia                        Compositions and methods for treating autoimmune diseases.

0603383        E162,714          Austria                           Compositions and methods for treating autoimmune diseases.

0603383                                 Belgium                         Compositions and methods for treating autoimmune diseases.

                  0603383                                 Denmark                       Compositions and methods for treating autoimmune diseases.

0603383                                 Europe                          Compositions and methods for treating autoimmune diseases.

                  Patent No.     National          Country                     Title

Patent No.

                  0603383                                 France                           Compositions and methods for treating autoimmune diseases.

0603383        69316729.7      Germany                       Compositions and methods for treating autoimmune diseases.

0603383        980400879       Greece                          Compositions and methods for treating autoimmune diseases.

0603383                                 Ireland                           Compositions and methods for treating autoimmune diseases.

0603383                                 Italy                                Compositions and methods for treating autoimmune diseases.

0603383                                 Luxembourg                  Compositions and methods for treating autoimmune diseases.

0603383                                 Monaco                         Compositions and methods for treating autoimmune diseases.

0603383                                 Netherlands                  Compositions and methods for treating autoimmune diseases.

0603383                                 Portugal                        Compositions and methods for treating autoimmune diseases.

81891                                     Singapore                     Compositions and methods for treating autoimmune diseases.

0603383                                 Spain                             Compositions and methods for treating autoimmune diseases.

0603383                                 Sweden                         Compositions and methods for treating autoimmune diseases.

0603383                                 Switzerland                   Compositions and methods for treating autoimmune diseases.

                  0603383                                 United Kingdom            Compositions and methods for treating autoimmune diseases.

5646182                                 USA                               Methods for treating autoimmune diseases.

Hypercholesterolemia

1206936        60112872T2     Germany                       Phenylacetic acid compositions for treating or preventing hypercholesterolemia.

1048588                         Hong Kong               Phenylacetic acid compositions for treating or preventing hypercholesterolemia.

1206936                         United Kingdom         Phenylacetic acid compositions for treating or preventing hypercholesterolemia.

6,987,131                        USA                        Phenylacetic acid compositions for treating or preventing hypercholesterolemia.

Liposomal Therapies

2254772                         Canada                   Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.

  0906088                                 France                           Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.

0906088     69734713.3-     Germany                 Liposomal Antineoplastons Therapies with Markedly Improved

                       08                                                             Antineoplastic Activity.

  4320052                                 Japan                            Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.

  0906088                                 United Kingdom            Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.

                  6013278                                 USA                               Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.

                  Patent No.     National          Country                     Title

Patent No.

Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion

                  92391                                     Finland                          Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion.

1562                                       Kazakhstan                   Compositions and methods for treating autoimmune diseases.

5474                                       Latvia                             Compositions and methods for treating autoimmune diseases.

3518                                       Lithuania                       Compositions and methods for treating autoimmune diseases.

26099                                     Philippines                    Compositions and methods for treating autoimmune diseases.

163552                                   Poland                           Compositions and methods for treating autoimmune diseases.

139204                                   Republic of Korea         Compositions and methods for treating autoimmune diseases.

1809830                                 Russia                           Compositions and methods for treating autoimmune diseases.

42331                                     Taiwan                          Compositions and methods for treating autoimmune diseases.

                  15756                                     Ukraine                         Compositions and methods for treating autoimmune diseases.

4918193                                 USA                               Methods for treating autoimmune diseases.

 

Neoplastic disease / Purified

551109                                   Australia                        Purified antineoplaston fractions and methods of treating neoplastic disease.

1188218                                 Canada                         Purified antineoplaston fractions and methods of treating neoplastic disease.

162813                                   Denmark                       Purified antineoplaston fractions and methods of treating neoplastic disease.

302/1989                                Hong Kong                    Purified antineoplaston fractions and methods of treating neoplastic disease.

65960                                     Israel                             Purified antineoplaston fractions and methods of treating neoplastic disease.

2010265                                 Japan                            Purified antineoplaston fractions and methods of treating neoplastic disease.

2010676                                 Japan                            Purified antineoplaston fractions.

2057285                                 Japan                            Pharmaceutical compositions for neoplastic disease.

MY102918A                           Malaysia                        Purified antineoplaston fractions and methods of treating neoplastic disease.

200805                                   New Zealand                 Purified antineoplaston fractions and methods of treating neoplastic disease.

163595                                   Norway                          Purified antineoplaston fractions and methods of treating neoplastic disease.

82/4178                          SouthAfrica               Purified antineoplaston fractions and methods of treating neoplastic disease.

512894                           Spain                      Purified antineoplaston fractions and methods of treating neoplastic disease.

                  Patent No.     National          Country                     Title

Patent No.

4470970                         USA                        Purified antineoplaston fractions and methods of treating neoplastic disease.

4558057                         USA                        Purified antineoplaston fractions and methods of treating neoplastic disease.

4559325                         USA                        Purified antineoplaston fractions and methods of treating neoplastic disease.

Neurofibromatosis

                  683145                           Australia                  Methods for treating neurofibromatosis.

0680756        E183,390          Austria                           Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756                                 Belgium                         Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756                                 Denmark                       Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756                                 Europe                          Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756                                 France                           Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756        69511453.0      Germany                       Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756                                 Greece                          Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

1016408                                 Hong Kong                    Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756                                 Ireland                           Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756        26583/BE/9       Italy                                Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756                                 Lithuania                       Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756                                 Luxembourg                  Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756                                 Monaco                         Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756                                 Netherlands                  Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756                                 Portugal                        Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756                                 Slovenia                        Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

95/3500                                  South Africa                  Methods for treating neurofibromatosis.

0680756                                 Spain                             Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

                  Patent No.     National          Country                     Title

Patent No.

0680756                                 Sweden                         Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756                                 Switzerland                   Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

0680756                                 United Kingdom            Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

                  5391575                         USA                        Methods for treating neurofibromatosis.

Parkinson’s disease

638869                                   Australia                        Pharmaceutical compositions for use in treating Parkinson’s disease.

0500905                                 Austria                           Pharmaceutical compositions for use in treating Parkinson’s disease.

0500905                                 Belgium                         Pharmaceutical compositions for use in treating Parkinson’s disease.

                  0500905                                 Denmark                       Pharmaceutical compositions for use in treating Parkinson’s disease.

0500905                                 Europe                          Pharmaceutical compositions for use in treating Parkinson’s disease.

                  0500905                                 France                           Pharmaceutical compositions for use in treating Parkinson’s disease.

0500905        69114261.0      Germany                       Pharmaceutical compositions for use in treating Parkinson’s disease.

0500905        3018437           Greece                          Pharmaceutical compositions for use in treating Parkinson’s disease.

0500905        19057/BE/96     Italy                                Pharmaceutical compositions for use in treating Parkinson’s disease.

0500905                                 Luxembourg                  Pharmaceutical compositions for use in treating Parkinson’s disease.

0500905                                 Netherlands                  Pharmaceutical compositions for use in treating Parkinson’s disease.

28633                                     Philippines                    Methods for treating Parkinson’s disease.

91/6977                                  South Africa                  Pharmaceutical compositions for use in treating Parkinson’s disease.

0500905                                 Spain                             Pharmaceutical compositions for use in treating Parkinson’s disease.

0500905                                 Sweden                         Pharmaceutical compositions for use in treating Parkinson’s disease.

0500905                                 Switzerland                   Pharmaceutical compositions for use in treating Parkinson’s disease.

                  0500905                                 United Kingdom            Pharmaceutical compositions for use in treating Parkinson’s disease.

5089508                                 USA                               Methods for treating Parkinson’s disease.

Pharmaceutical composition comprising phenylacetylglutamine, etc.

0069232        E23113             Austria                           Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.

0069232                                 Belgium                         Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.

                  Patent No.     National          Country                     Title

Patent No.

                  1262907                                 Canada                         3-[N-Phenylacetylaminopiperidine]-2,6-dione and Process of Synthesizing Same.

0069232                                 Europe                          Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.

                  0069232                                 France                           Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.

0069232        P3273952.4      Germany                       Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.

0069232        22434/BE/86     Italy                                Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.

0069232                                 Luxembourg                  Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.

0069232                                 Netherlands                  Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.

0069232                                 Sweden                         Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.

0069232                                 Switzerland                   Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.

                  0069232                                 United Kingdom            Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.

 

 

Skin

0197358                                 Austria                           Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.

0197358                                 Belgium                         Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.

                  Patent No.     National          Country                     Title

Patent No.

                  1262866                                 Canada                         Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation.

0197358                                 Europe                          Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.

                  0197358                                 France                           Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.

0197358                                 Germany                       Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.

0197358                                 Italy                                Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.

1953215                                 Japan                            Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.

0197358                                 Luxembourg                  Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.

0197358                                 Netherlands                  Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.

0197358                                 Sweden                         Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.

0197358                                 Switzerland                   Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.

                  0197358                                 United Kingdom            Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.

                  4593038                                 USA                               Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation.

Synthesis of 4-phenylbutyric acid.

2447803                                 Canada                         Synthesis of 4-phenylbutyric acid.

  ZL02810264.9                        China                            Synthesis of 4-phenylbutyric acid.

  1404638                                 Europe                          Synthesis of 4-phenylbutyric acid.

                                                                                        The European patent has been validated in the following contracting countries: Belgium (BE), Cyprus (CY), Germany (DE), France (FR), United Kingdom (GB), Ireland (IE), Liechtenstein (LI), Monaco (MC), Republic of Turkey (TR).

  1065996                                 Hong Kong                    Synthesis of 4-phenylbutyric acid.

  229996          P0400053         Hungary                        Synthesis of 4-phenylbutyric acid.

  229199                                   India                              Synthesis of 4-phenylbutyric acid.

  158914                                   Israel                             Synthesis of 4-phenylbutyric acid.

  4338401                                 Japan                            Synthesis of 4-phenylbutyric acid.

  201802          P364646           Poland                           Synthesis of 4-phenylbutyric acid.

  10-0905139                            Republic of Korea         Synthesis of 4-phenylbutyric acid.

2297998                         Russia                    Synthesis of 4-phenylbutyric acid.

                  Patent No.     National          Country                     Title

Patent No.

 

  0101088                                 Singapore                     Synthesis of 4-phenylbutyric acid.

6372938 B1                     USA                        Synthesis of 4-phenylbutyric acid.

Testing procedure to aid diagnosis of cancer and evaluate the progress of cancer therapy

4444890                                USA                                Testing procedure to aid diagnosis of cancer and evaluate the progress of cancer therapy.

Toothpaste

7087219                                USA                                Toothpaste Containing Anticancer Agents.

Treatment of Neoplastic Disease

  1098643                         Austria                    Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the treatment of neoplastic disease.

ZL200410061600.5            China                     A composition for treating neoplastic disease and the use thereof.

1098643                         Europe                    Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the treatment of neoplastic disease.

1098643                        Finland                    Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the treatment of neoplastic disease.

1098643                         France                    Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the treatment of neoplastic disease.

1098643     69914084.6-     Germany                 Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for

                       08                                                             the treatment of neoplastic disease.

  227008                           India                       A Phamaceutical Composition Comprising Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the Treatment of Neoplastic Disease.

  509244                           New Zealand             A Phamaceutical Composition Comprising Phenylacetate and Phenylacetylglutamine.

0414587                        Republic of Korea       A Phamaceutical Composition Comprising Phenylacetate and Phenylacetylglutamine.

0417100                         Republic of Korea       A Phamaceutical Composition Comprising Phenylacetate and Phenylacetylisoglutamine.

  0417101                         Republic of Korea       A Pharmaceutical Composition Comprising an Aqueous Solution of Phenylacetate.

 

Treatment Regimen

759278                           Australia                  Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

1098643                         Belgium                   Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

2336945                         Canada                   Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

ZL99811314.X                  China                     Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

                  Patent No.     National          Country                     Title

Patent No.

1098643                         Denmark                  Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

004179                           Eurasia                    Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

The Eurasian patent has been validated in the following contracting countries: Azerbaijan, Armenia, Belarus, Kazakhstan, Kyrgyzstan, Moldova, and The Russian Federation.

1098643                         Greece                    Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

01107897.8                     Hong Kong               Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

ID0012068                      Indonesia                 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

ID0013227                      Indonesia                 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

140848                           Israel                      Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

1098643                         Italy                        Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

1098643                         Latvia                      Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

1098643                         Luxembourg              Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

222968                           Mexico                    Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

1098643                         Netherlands              Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

509244                           New Zealand             Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

213698                           Poland                    Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

1098643                         Portugal                  Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

399658                           Republic of Korea       Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

78643                            Singapore                Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

2001/0622                       South Africa              Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

1098643     2214866         Spain                      Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

1098643                         Sweden                   Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

1098643                         Switzerland               Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

                  Patent No.     National          Country                     Title

Patent No.

1098643                         United Kingdom         Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

6258849                         USA                        Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

6943192B2                      USA                        Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

VHL

012908                           Eurasia                    Method for treatment of Von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives.

The Eurasian patent has been validated in the following contracting countries: Azerbaijan (AZ), Kazakhstan (KZ), and Russia (RU).

1855665                         Europe                    Use of phenylacetyl-derivatives for the manufacture of a medicament to treat Von Hippel-Lindau (VHL) disease.

1855665                         Germany                 Use of phenylacetyl-derivatives for the manufacture of a medicament to treat Von Hippel-Lindau (VHL) disease.

1855665                         United Kingdom         Use of phenylacetyl-derivatives for the manufacture of a medicament to treat Von Hippel-Lindau (VHL) disease.

Viral infections

0601164                                 Austria                           Methods for treating viral infections.

0601164                                 Belgium                         Methods for treating viral infections.

                  0601164                                 Denmark                       Methods for treating viral infections.

0601164                                 Europe                          Methods for treating viral infections.

                  0601164                                 France                           Methods for treating viral infections.

0601164        69327642.8      Germany                       Methods for treating viral infections.

0601164                                 Greece                          Methods for treating viral infections.

0601164                                 Ireland                           Methods for treating viral infections.

0601164                                 Italy                                Methods for treating viral infections.

0601164                                 Luxembourg                  Methods for treating viral infections.

0601164                                 Monaco                         Methods for treating viral infections.

0601164                                 Netherlands                  Methods for treating viral infections.

0601164                                 Portugal                        Methods for treating viral infections.

67344                                     Singapore                     Methods for treating viral infections.

0601164                                 Spain                             Methods for treating viral infections.

0601164                                 Sweden                         Methods for treating viral infections.

0601164                                 Switzerland                   Methods for treating viral infections.

                  0601164                                 United Kingdom            Methods for treating viral infections.

                  Patent No.     National          Country                     Title

Patent No.

                  5244922                                 USA                               Methods for treating viral infections.

 

 

 

 

Trade Name

Tradename No.                        Country                     Title

 

Reg.No.: CDN-HY-             China                      China Domain Name Registration Certificate.  Internet Keyword:

07011055; (56); (57).                                                      Aminocare.  Valid until: 5/23/2017

China Domain Name Registration Certificate.  Internet Keyword: Aminocare.cn.  Valid until: 5/23/2012

China Domain Name Registration Certificate.  Internet Keyword: Aminocare.com.cn.  Valid until: 5/23/2012

Trademarks

Trademark No.                        Country/State              Title

 

10328784                        China                      Avavital in Class 5

10328785                        China                      Atengenal in Class 5

10328787                        China                      Cengenal in Class 5

10328788                        China                      Fengenal in Class 5

46957304                        China                      Aminocare

004006102                      Europe                    Fengenal in Class 5

004006334                      Europe                    Avavital

004006359                      Europe                    Bugenal in Class 5

004006375                      Europe                    Lubgen Farma in Classes 39 (distribution of pharmaceutical preparation) and in Class 40 (custom manufacturing of pharmaceutical preparations for others)

004006425                      Europe                    Cengenal in Class 5

004006664                      Europe                    Astugenal in Class 5

004006979                      Europe                    Atengenal in Class 5

300343377                      Hong Kong               Aminocare in Class 5

302118276                      Hong Kong               Avavital in Class 5

302118285                      Hong Kong               Atengenal in Class 5

302118294                      Hong Kong               Astugenal in Class 5

302118302                      Hong Kong               Cengenal in Class 5

302118311                      Hong Kong               Fengenal in Class 5

  247442                                   Israel                              Fengenal in Class 5

  247444                                   Israel                              Cengenal in Class 5

  247445                                   Israel                              Astugenal in Class 5 – ONLY EMAIL, NO ORIGINAL

  247446                                   Israel                              Atengenal in Class 5

  247447                                   Israel                              Avavital in Class 5

Trademark No.                        Country                     Title

 

41914                            Kazakhstan               Fengenal in Class 5

41913                            Kazakhstan               Astugenal in Class 5

41912                            Kazakhstan               Atengenal in Class 5

41911                            Kazakhstan               Avavital in Class 5

41910                            Kazakhstan               Fengenal in Class 5

41909                            Kazakhstan               Aminocare in Class 5

67271                            Lithuania                  Fengenal in Class 5

67272                            Lithuania                  Cengenal in Class 5

67273                            Lithuania                  Astugenal in Class 5

67274                            Lithuania                  Atengenal in Class 5

67562                            Lithuania                  Avavital in Class 5

67275                            Lithuania                  Aminocare in Class 5

N/062073                        Macau                     Fengenal in Class 5

N/062074                        Macau                     Cengenal in Class 5

N/062075                        Macau                     Astugenal in Class 5

N/062076                        Macau                     Atengenal in Class 5

N/062077                        Macau                     Avavital in Class 5

N/062078                        Macau                     Aminocare in Class 5

  2012054846                     Malaysia                  Fengenal in Class 5

2012054860                     Malaysia                  Cengenal in Class 5

2012054844                     Malaysia                  Avavital in Class 5

2012054843                     Malaysia                  Atengenal in Class 5

2012054850                     Malaysia                  Astugenal in Class 5

1598.40.01                      Philippines                Fengenal in Class 5

1598.40.02                      Philippines                Cengenal in Class 5

1598.40.03                      Philippines                Astugenal in Class 5

1598.40.04                      Philippines                Atengenal in Class 5

1598.40.05                      Philippines                Avavital in Class 5

1598.40.06                      Philippines                Aminocare in Class 5

188750                           Poland                    Lubgen Farma

  120234                                   Republic of Korea         Lubgen Farma in Class 35 (Arranging of pharmaceutical sales)

  129501                                   Republic of Korea         Lubgen Farma in Class 40 (custom manufacturing of pharmaceutical preparations for others)

Trademark No.                        Country                     Title

 

620203                           Republic of Korea       Bugenal in Class 5

622094                           Republic of Korea       Astugenal in Class 5

622095                           Republic of Korea       Atengenal in Class 5

622096                           Republic of Korea       Avavital in Class 5

622097                           Republic of Korea       Cengenal in Class 5

622098                           Republic of Korea       Fengenal in Class 5

292206                           Russia                     Astugenal in Class 5

293368                           Russia                     Bugenal in Class 5

300114                           Russia                     Cengenal in Class 5

  304514                                   Russia                           Lubgen Farma in Class 35 (Arranging of pharmaceutical sales) and in Class 40 (custom manufacturing of pharmaceutical preparations for others)

  304679                                   Russia                           Avavital in Class 5

  304680                                   Russia                           Atengenal in Class 5

  304681                                   Russia                           Fengenal in Class 5

327323                           Russia                     Aminocare in Class 5

01165897                        Taiwan                    Aminocare in Class 5

01543739                        Taiwan                    Fengenal in Class 5

01543740                        Taiwan                    Cengenal in Class 5

01543741                        Taiwan                    Astugenal in Class 5

01543742                        Taiwan                    Atengenal in Class 5

01543743                        Taiwan                    Avavital in Class 5

  853930                                   Thailand                        Fengenal in Class 5

  853931                                   Thailand                        Cengenal in Class 5

  853932                                   Thailand                        Astugenal in Class 5

  853933                                   Thailand                        Atengenal in Class 5

  050590                                   USA                                State Trademark ‘Antineoplaston’ – Texas

1719793                         USA                        Federal trademark ‘Antineoplaston’ for pharmaceuticals.

2999213                         USA                        Bugenal in Class 5

  3142996                                 USA                                Ampolgen Pharmaceuticals, LLC.  In Classes 35 and 42.

3160376                         USA                        Aminocare in Class 6

3169436                         USA                        Avavital in Class 5

3174860                         USA                        Fengenal in Class 5

3177785                         USA                        Astugenal in Class 5

Trademark No.                        Country                     Title

 

318432                           USA                        Atengenal in Class 5

3276180                         USA                        Cengenal in Class 5

  200989                                   Vietnam                         Cengenal in Class 5

  200990                                   Vietnam                         Astugenal in Class 5

  200991                                   Vietnam                         Atengenal in Class 5

  200992                                   Vietnam                         Avavital in Class 5

  205522                                   Vietnam                         Fengenal in Class 5

Request an Appointment